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Abstract
ABSTRACT
UNDERSTANDING THE ROLE OF SPIRITUAL WELL-BEING
IN A SMOKING CESSATION PROGRAM
Kia Kerrin, MSW
Ram Cnaan, Ph.D.
Tobacco use, particularly cigarette smoking,, is the single most preventable cause of death in the United
States of America. The negative health effects of cigarette smoking are a major public health concern
that can be reduced through quitting. Preliminary data has shown that spirituality can aid in the success
of addiction treatment programs and smoking cessation programs. However, the current data are limited
in their support of the relationship between spirituality and smoking cessation. This research study
further explored the relationship between spiritual well-being and smoking cessation. A sample of 178
cigarette smokers was included in the research study to assess the relationship between levels of
spiritual well-being and abstinence after an 8 week nicotine patch smoking cessation treatment program.
The study was conducted through the University of Pennsylvania and Northwestern University. The
proposed study was completed in conjunction with an ongoing NIH-funded clinical trial (R01 DA025078;
An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence). The proposed study involved
the inclusion of a spiritual well-being scale at the baseline session. Subjects received the 21mg
transdermal nicotine patch for 8 weeks, along with smoking cessation counseling. The Spiritual Well
Being scale was utilized to determine if spiritual well-being was a predictor of abstinence at the 8 week
mark. This research study was intended to be a catalyst to determine whether spirituality should play a
part in smoking cessation programs. Concerning the relationship between the spiritual well-being scale
and quitting smoking and the spiritual well-being scale and dropping out of the smoking cessation
program, there were no significant findings. Although, these main relationships were not found there were
other significant relationships that may suggest these areas should be explored in more depth.
Relationships were found between religious well-being and compliance with patch usage. The initial
findings also suggest there is a relationship between scores of religious well - being and race.
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ABSTRACT
UNDERSTANDING THE ROLE OF SPIRITUAL WELL-BEING
IN A SMOKING CESSATION PROGRAM
Kia Kerrin, MSW
Ram Cnaan, Ph.D.

Tobacco use, particularly cigarette smoking, is the single most preventable cause of death
in the United States of America. The negative health effects of cigarette smoking are a major
public health concern that can be reduced through quitting. Preliminary data has shown that
spirituality can aid in the success of addiction treatment programs and smoking cessation
programs. However, the current data are limited in their support of the relationship between
spirituality and smoking cessation. This research study further explored the relationship between
spiritual well-being and smoking cessation. A sample of 178 cigarette smokers was included in
the research study to assess the relationship between levels of spiritual well-being and abstinence
after an 8 week nicotine patch smoking cessation treatment program. The study was conducted
through the University of Pennsylvania and Northwestern University. The proposed study was
completed in conjunction with an ongoing NIH-funded clinical trial (R01 DA025078; An
Effectiveness Trial of Maintenance Therapy for Nicotine Dependence). The proposed study
involved the inclusion of a spiritual well-being scale at the baseline session. Subjects received
the 21mg transdermal nicotine patch for 8 weeks, along with smoking cessation counseling. The
Spiritual Well Being scale was utilized to determine if spiritual well-being was a predictor of
abstinence at the 8 week mark. This research study was intended to be a catalyst to determine
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whether spirituality should play a part in smoking cessation programs. Concerning the
relationship between the spiritual well-being scale and quitting smoking and the spiritual wellbeing scale and dropping out of the smoking cessation program, there were no significant
findings. Although, these main relationships were not found there were other significant
relationships that may suggest these areas should be explored in more depth. Relationships were
found between religious well-being and compliance with patch usage. The initial findings also
suggest there is a relationship between scores of religious well - being and race.
Keywords: spiritual well-being, smoking cessation
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Chapter 1: Spirituality
Spirituality is a complex and difficult concept to capture. It is one of those concepts that
almost everyone knows exists and yet, when people discuss it and attempt to define it, they find
the concept elusive. Often people claim that they gain strength and moral guidance from their
spirituality yet they cannot put a finger on what spirituality “is”. As this dissertation focuses on
the power of spirituality in smoking cessation, it is important to define it and review the state of
knowledge regarding its’ meaning and power.
Definition of Spirituality
Spirituality has been defined in several ways. Some state that spirituality and religion are
synonymous, while others feel spirituality does not have to correlate with a particular religion or
God. The Merriam-Webster dictionary defines spirituality as 1: something that in ecclesiastical
law belongs to the church or to a cleric as such; 2: clergy; 3: sensitivity or attachment to
religious values; and 4: the quality or state of being spiritual. This definition emphasizes religion
as it pertains to spirituality.
The National Interfaith Coalition on Aging (1975) described spiritual well being as “the
affirmation of life in a relationship with God, self, community and environment that nurtures and
celebrates wholeness.” This definition states the relationship with God, as well as, other
important entities in one’s life such as self and community. This is a slightly more holistic
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approach to understanding spirituality. The connection between self and the environment or self
and the community can be a spiritual understanding.
Hawks et al. (1995) defined spirituality as a sense of relatedness or connectedness to
others, a provision for meaning and purpose in life, the fostering of well-being (through a stress
buffering effect), and having a belief in and a relationship with a power higher than oneself.
This definition begins to explore the two dynamics of spirituality: the connectedness to others
and meaning and purpose in life, as well as, a religious connection, i.e., a relationship with a
higher power. This concept stresses the understanding of purpose in life as a spiritual journey.
The understanding of meaning and purpose in life may not include the belief in a higher being
but often does for those practicing religion.
Spirituality can be understood as a dynamic principle that guides a person’s view of the
world and relationship with a higher life force, as well as providing a sense of hope, moral
conviction, faith, love, and trust (Hicks, 1999). Again, the definition separates two key
dimensions: 1) a view of the world, and 2) a belief in a higher life force. This definition takes
the concept even further by stating that spirituality provides hope, moral, conviction, faith, love
and trust, all elements which may be helpful in a therapeutic intervention.
The existence of a higher being or an essence other than oneself has been debated for
generations. Even though the existence is debatable, the fact that many Americans identify with
a religion and/or spirituality cannot be denied. If religion and spirituality is a tool used in one’s
life why should it be excluded from therapy? With the push of evidence-based practice it is
necessary to study whether religion or spirituality can play a role in the success of a therapeutic
program. For this reason the proposed study, Understanding the Role of Spiritual Well-Being in

Running Head: Smoking Cessation Treatment

10

a Smoking Cessation Program, will explore spirituality through the use of a quantitative
measure, the Spiritual Well Being Scale. The Spiritual Well-Being Scale constructed by
Paloutzian & Ellison (1982, 1991) is the most widely used instrument for both research and
clinical evaluations of spirituality.

Relevance of Spirituality
Spirituality is often left out of the therapist/client dialogue because of beliefs that they are
not necessarily related to the direct therapy. Spirituality is often seen as not being a tangible tool
for therapists to use in a session and for that reason not valued. Strategies such as cognitivebehavioral therapy are more easily manualized and defined and therefore justified for a
counseling session. The relevance of spirituality and religion are further being studied and
findings are promising.
Koenig (2007), described the relationship between religion, spirituality and health
outcomes. Koenig, stated the following:
“What exactly is “religious coping”? Religious coping is the use of
religious beliefs or practices to reduce the emotional distress caused by
loss or change. Patients may “turn over” their problems to God, trusting
God to handle them so that they don’t have to ruminate or worry about
them. They may believe that God has a purpose in allowing them to
experience pain or suffering, which givers suffering meaning and makes it
more bearable. A host of religious cognitions like these are mobilized to
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reduce anxiety, increase hope, or increase a sense of control. With regard
to religious practices that facilitate coping, patients may pray, mediate,
read religious scriptures, attend religious services, perform religious rituals
(receive the sacraments or be anointed with oil for example) or rely on
support from clergy or members of their church, synagogue, mosque or
temple. Religious beliefs and practices, then, are used to regulate emotion
during times of illness, change and circumstances that are out of patients’
personal control (pp 20).”
In recent years, the scientific study of religion related to age and its’ importance
for coping with the stresses of life has become more accepted and acknowledged (Levin
& Koenig, 2004). Murdock (date) randomly sampled nearly 300 gerontology social
workers and found that social workers tend to think favorably about religion and
spirituality, as part of a holistic response to the needs of their diverse clientele. Yet, a
substantial proportion (70%) admitted they had only minimal preparation for dealing with
religion or spirituality. The therapists appear ready to explore these strategies with their
client base but the field is not properly preparing the social workers. With more
supportive research, the field could take religion and spirituality more seriously.
Organized social work in the 20th century tried to distance itself from its origins
which were in the form of religious charity in favor of becoming a scientific and
professional enterprise (Moody, 2005). It is only recently that social work has come to a
more favorable view of religion (Cnaan et al., 1999). This change in viewpoint could be
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due to recent increase in research on religion and spirituality. However, this field has
more room to grow.
Interest in the impact of spirituality has been shown in other fields besides social
work such as the medical field. The need for training to integrate spirituality into patient
care has been increasingly recognized within medical education. In 1992, only three
medical schools offered courses on religion, spirituality and medicine. By 2006, over one
hundred of the 141 medical schools in the U.S. and Canada had some courses in
spirituality and medicine (70 percent of which are required; Puchalski, 2006). The next
step is from courses, to research, and to applied evidence-based practice.
By the year 2000, the number of studies examining the relationship between some
aspect of religion, spirituality and health or health-care had grown to nearly 1,200, about
70 percent of which were on mental health and 30 percent on physical health (Koenig,
McCullough, & Larson 2001). Koenig et al. further (2001) stated, the following:
“It appears that psychological and social factors influence the physiological
systems of the body that are directly responsible for good health and the
ability to fight disease. Therefore, if religious/spiritual involvement can be
shown to enhance psychological health and social interactions; it is
reasonable to hypothesize that religious factors may improve physical health
as well doing so by reducing psychological stress, increasing social support
and encouraging positive health behaviors (p.53).
Koenig et al. (2001), Moody (2005), Cnaan et al. (1999), and Puchalski (2006) support
the relevance of spirituality in the field of public health, including for smoking cessation. This

Running Head: Smoking Cessation Treatment

13

paper will focus mainly on spirituality as it relates to substance abuse and smoking cessation.
The following section will explore research in spirituality and substance abuse.
Spirituality and Substance Abuse
The use of spirituality has been studied in several forms of addiction treatment.
Participants have shown interest in using spirituality as part of their treatment and spirituality
may also aid in their quit attempt. Understanding spirituality in other forms of addiction can
support exploring the use of spirituality in smoking cessation counseling. Investigators have
found that aspects of spirituality may be related to recovery from addiction (Kelly et al., 2011).
As we consider other drug addiction treatments, it is notable that the success of
Alcoholics Anonymous is generally attributed to its strong spiritual focus (Alcohol Anonymous,
1952). Kelly et al. (2011) examined the relationship among Alcoholic Anonymous,
spirituality/religiousness, and alcohol use, and tested whether the observed relation between AA
and better alcohol outcomes can be explained by spiritual changes. Controlling for a variety of
confounding variables, attending Alcoholic Anonymous was associated with increases in
spiritual practices, especially for those initially low on this measure at the time of intake. Results
also showed that AA was consistently associated with better subsequent alcohol outcomes,
which was partially mediated by increases in spirituality. This meditational effect was
demonstrated in both outpatients and aftercare samples and both alcohol outcomes (proportion of
abstinent days; drinks per drinking days). Kelly and colleagues’ study supports the association
between spirituality and success in recovery but also the increase in spirituality lead to success.
This supports the fact that therapists should discuss this in sessions in an attempt to increase
client spirituality which can possibly increase success rates.
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Spirituality and substance use are strongly related in twelve step programs, such as,
Alcoholic Anonymous. In 1939, Bill W. (one of the co-founders of Alcoholic Anonymous)
stated that men and women with substance abuse problems “have been not only mentally and
physically ill, they have been spiritually sick: (AA World Services, 2001, pp.64).
Alcoholics Anonymous® is a fellowship of men and women who
share their experience, strength and hope with each other that they may
solve their common problem and help others to recover from
alcoholism. The only requirement for membership is a desire to stop
drinking. There are no dues or fees for AA membership; we are selfsupporting through our own contributions. AA is not allied with any
sect, denomination, politics, organization or institution; does not wish
to engage in any controversy, neither endorses nor opposes any causes.
Our primary purpose is to stay sober and help other alcoholics to
achieve sobriety (Alcoholic Anonymous, 2011)
There are particular elements of the AA meetings that have spiritual elements such as
saying the serenity prayer and the following:
•

admitting that one cannot control one's addiction or compulsion;

•

recognizing a higher power that can give strength;

•

examining past errors with the help of a sponsor (experienced member);

•

making amends for these errors;

•

learning to live a new life with a new code of behavior; and

•

helping others who suffer from the same addictions or compulsions.
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The use of spirituality or religion is not new as it has been prevalent in the twelve step
program which has a Protestant foundation (Miller, 1998). This limits the ability to generalize
results to other religions and beliefs. However, there are clearly lined out elements (such as
prayer or a belief of a higher power) of spirituality in AA that could be explored in a counseling
session or used as a foundation to manualize how to approach spiritual in a session if a client is
interested.
The use of spirituality in treating addiction is not only used in AA but also in other
research studies and treatments for addiction. Heinz, Disney, Epstein, Glezen, and Clark (2010)
used focus groups in 2005-2006 with 25 urban methadone-maintained outpatients to examine
beliefs about the role of spirituality in addiction and its appropriateness in formal treatment.
They found that spirituality and religious practices suffered during active addiction but went
“hand-in-hand” with recovery. Participants agreed that integration of a voluntary spiritual
discussion group into formal treatment would be preferable to currently available alternatives
(Heinz et. al., 2010).
The relationship of spirituality, religiosity and self-efficacy with drug and/or alcohol
cravings was researched by Mason, Deane, Kelly, and Crowe (2009). In their study, 77 male
participants at an Australian Salvation Army ages 19 to 74 years old completed a cross-sectional
survey. Of the clients, 75% reported that spirituality and religious faith were useful components
of the treatment program; however, spirituality and self-efficacy had significant relationships
with cravings. Self-efficacy mediated the relationship between spirituality and drug and/or
alcohol cravings. This research expresses the importance of spirituality and religion which
supports the need for clinicians to research and address this area.
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Galanter, Dermatis, Bunt, Williams, and Trujilo (2007) used a 6-item Spirituality SelfRating Scale to reflect a global measure of spiritual orientation to life. The scale and the
measures related to recovery from addiction and treatment response were applied in three diverse
treatment settings: 1) a general hospital inpatient psychiatry service, 2) a residential therapeutic
community, and 3) a methadone maintenance program. Findings on these patient groups were
compared to responses given by undergraduate college students, medical students, addiction
faculty, and chaplaincy trainees. The results showed that for certain patients spiritual orientation
is an important aspect of their recovery (Galanter et al., 2007). Once again the elements of
spiritual well-being have been seen as helpful in fighting addictions. Spirituality as a tool in
recovery for alcohol and drug abuse has been studied and research has shown correlation
between increase in spirituality and success rates. Spirituality and smoking cessation has been
relatively under-studied but there are some studies that have supported the use of spirituality for
smoking cessation.
Spirituality and Smoking Cessation
Gonzales and colleagues (2007) noted that patient spiritual resources are increasingly
included in the treatment of medical conditions such as cancers and alcohol and drug
dependence, but use of spiritual resources is usually excluded from tobacco dependence
treatment. Gonzales and colleagues’ study concluded that smokers, especially heavy smokers,
may be receptive to using spiritual resources in a quit attempt and that spirituality in tobacco
dependence treatment warrants additional investigation and program development. This
supports the need for more research in the area of smoking cessation and spirituality which is the
focus of the proposed study.
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Koenig et al. (2001) reviewed a growing body of literature suggesting that aspects of
spirituality are related to healthy lifestyles; including being a non-smoker, coping with stress,
and recovery from addiction. Smoking cessation has major and immediate health benefits that
aide in decreasing the risk of heart attacks, strokes, chronic lung disease and various cancers
including lung cancer (NCI, 2010).
Hawks et al. (1995) stated that health educators are in a position to develop, implement,
and evaluate spiritual health interventions within the context of comprehensive programs.
Imagery, mediation, and group support activities may address various components of spiritual
health such as meaning and purpose in life, self-awareness, and connectedness with self and
others. In researching the effects of a quit attempt, results can show the relevance and the
personal need for including spiritual health in smoking cessation counseling.
Some populations may benefit more from a spiritual or religious element to smoking
cessation than others. In Kaholokula’s (2008) study former and current Native American
smokers were studied for the purpose of developing a culturally informed smoking cessation
program. The study consisted of ten focus groups with a total of 52 Native Hawaiian men and
women from a rural community in Hawaii. The transcriptions resulted in 11 strategies, 23
supports, and 13 barriers to smoking cessation. Native Hawaiians reported having used more
behavioral and religious/spiritual strategies to quit smoking compared with other smokers.
Religion and spirituality is important in the Native Hawaiian culture and for this reason it was a
vital part in their smoking cessation success (Kaholokula, 2008).
The influence of religious and spiritual beliefs as it relates to choices about health can
began as early as childhood. Another study used data from a nationally representative sample of
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US adolescents in grades 7 through 12 to explore the effects of public and private religiosity on
initiation, escalation, and cessation of smoking (Nonnemaker, McNeely, & Blum, 2006). The
study found that adolescents' decisions to experiment with smoking are influenced by both their
individual practice of their faith and by participation in a larger faith community. Private
religiosity was protective against initiation of regular smoking and initiation of experimental
smoking among nonsmokers but only when the young person frequently attended religious
services or a religious youth group. In contrast, public religiosity did predict reduction and
cessation of cigarette use among regular smokers. The above mentioned study brings up the
complexity of the term religiosity and whether the participants were active in their place of
worship but it does show some value in religion in smoking habits or religious leaders. Also,
these findings may not be applicable to an adult population.
These findings of the relationship between spirituality and smoking can be detected in the
Koenig (1998) study as well. The Koenig (1998) study of 3968 persons age 65 and older showed
that religiously active persons are less likely to smoke cigarettes, and if they do smoke, they
smoke fewer cigarettes than who?. Given the association between smoking and disease, and the
widespread prevalence of both smoking and religious activity, this finding has implications for
public health, namely, positive associations between religious practices and health behaviors.
McFadden et al. (2011) assessed the potential impact of spiritual beliefs on lifestyle
choices such as tobacco use. A patient survey was conducted and among 501 patients who
participated, 370 were nonsmokers and 131 were smokers. Compared with smokers,
nonsmokers more often participated in religious activities such as regular weekly church
attendance daily prayer and Bible study (48% vs. 24%). Current smoking was negatively

Running Head: Smoking Cessation Treatment

19

correlated with religious activities. From this study we can deduce that nonsmokers are more
likely to engage in religious activities such as prayer, Bible study and regular church attendance.
Could there be a fall in religious beliefs or activities that make clients more likely to fail in their
quit attempt? Revisiting their religious or spiritual strengths and reconnecting them to these
factors could play a vital role in recovery.
Smoking cessation has many health benefits; for this reason many smoking cessation
programs and medications have been developed to aid smokers in the quitting process. The
previous studies discussed the interest of spirituality and religion being incorporated in smoking
cessation programs.
Non-Christian Spirituality and Smoking Cessation
In the United States, spirituality is often discussed in respect to a Judeo-Christian
doctrine; however, spirituality can take many forms in different religions. The following section
looks into Buddhist and Muslim spirituality in order to better understand the complexity of the
concept. In the Yong et al. (2009) study a prospective examination of the perceived relevance
and role of religion and religious authorities in influencing smoking behavior among Muslims in
Malaysia and Buddhists in Thailand were conducted. Survey instruments were given and data
were collected from 1482 Muslim Malaysians and 1971 Buddhist respondents. Results revealed
that over 90% of both religious groups reported that their religion guides their day-to-day
behavior at least sometimes, but Malaysian Muslims were more likely to report that this was
always the case. Currently, religion and spirituality is still playing a large role in people’s lives
yet we are still leaving this major aspect of one’s life out of our sessions.

Running Head: Smoking Cessation Treatment

20

In the Beitel et al. (2007) study a spirituality-focused manual was created for the
treatment of addiction and HIV-risk behavior. The theoretical base was pulled from cognitive
psychology and Buddhist philosophy which could make it suitable for individuals of diverse
faiths. The therapy development process began with focus groups. The therapy was then codified
in manual format, and a controlled clinical trial was conducted. The participant’s experiences
were recorded and coded. The results show that participants supported and valued an integration
of spiritual-focused interventions in addiction treatment (Beitel et al., 2007). Developing
manuals to teach spirituality to therapist would be invaluable especially if more research is
proven to show their correlation.
Spirituality has shown to have an impact on one’s health outcomes and for this reason
should be explored more in research. In the future, spirituality could be looked at as a tool for
recovery just as cognitive-behavioral therapy is used as a method of recovery. It is important to
have effective smoking cessation programs as cigarette smoking can be detrimental to the health
of the cigarette smoker and even those exposed to secondhand smoke.
Chapter 2: Smoking
According to the National Institute of Drug Abuse, tobacco use, particularly cigarette
smoking, is the single most preventable cause of death in the United States (NIDA, 2009).
Smoking cigarettes can be detrimental to the health of a cigarette smoker as well as to those who
are exposed to the smoke. However, due to various addictive properties of the nicotine
components within the cigarettes, reducing usage or quitting entirely can be very challenging for
cigarette smokers who want to quit. Through the use of tobacco, nicotine is one of the most
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heavily used addictive drugs and the leading preventable cause of disease, disability, and death
(NIDA, 2009).
Health Effects of Cigarette Smoking
In the United States of America, cigarette smoking accounts for 90% of lung cancer
cases and approximately 38,000 deaths per year as a result of secondhand smoke (NIDA, 2009).
The tar in cigarettes increases a smoker's risk of lung cancer, emphysema, and bronchial
disorders. The carbon monoxide in smoke increases the chance of cardiovascular diseases
(NIDA, 2009).
Cigarette smoking is responsible for approximately 443,000 deaths—one in every five
deaths—each year in the United States. The chronic diseases caused by tobacco use lead the
causes of death and disability in the United States and unnecessarily strain our health care
system. The economic burden of cigarette use includes more than $193 billion annually in health
care costs and loss of productivity (CDC, 2011).
The adverse health effects for cigarette smoking accounts for nearly 1 of every 5 deaths,
each year in the United States (CDC). The negative effects from the use of cigarettes, plagues
many Americans, as well as their family members. According to the Center for Disease Control
and Prevention, smoking harms nearly every organ of the body, causing many diseases and
reducing the health of smokers in general (see figure 1).

Figure 1: The health consequences causally linked to smoking and exposure to secondhand
smoke
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United States Department of Health and Human Services (1988)
Cigarette smoking not only harms the smoker, but it can also harm others who inhale the
second hand smoke. According to the United States Department of Health and Human Services
(1988), there are no risk-free levels of exposure to secondhand smoke. Nonsmokers exposed to
secondhand smoke at home or work increase their risk of developing heart disease by 25 to 30
percent and lung cancer by 20 to 30 percent. The finding is of major public health concern due to
the fact that nearly half of all nonsmoking Americans are still regularly exposed to secondhand
smoke. Secondhand smoke contains more than 50 cancer-causing chemicals, and is itself a
known human carcinogen. Table 2, from the U.S. Department of Health and Human Services
(2004, 2006), lists causal relationships between smoking and diseases.

Table 1: Causal conclusions on smoking and diseases of the respiratory tract other than
lung cancer: the 2004 and 2006 reports of the Surgeon General

Active Smoking
The evidence is sufficient to infer a causal conclusion between smoking and
• Acute respiratory illnesses, including pneumonia, in persons without underlying
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Involuntary Exposure to Tobacco Smoke
The evidence is sufficient to infer a causal conclusion between secondhand smoke
exposure
From parental smoking and
• Lower respiratory illnesses in infants and children
• Middle ear disease in children, including acute and recurrent otitis media and chronic
middle ear effusion
• Cough, phlegm, wheeze, and breathlessness among children of school age
• Ever having asthma among children of school age
• Onset of wheeze illnesses in early childhood
From maternal smoking during pregnancy and
• Persistent adverse effects on lung function across childhood
After birth and
• Lower level of lung function during childhood
And
• Odor annoyance
• Nasal irritation
Source: U.S. Department of Health and Human Services 2004, 2006
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Smoking and lung cancer
Tobacco's role in increasing the chance of lung cancer is one of the most widely known
facts of tobacco’s harmful effects on human health. Smokers carry an additional risk of 10- to
20- fold of developing lung cancer compared to non-smokers (23 times for men and 13 times for
women smokers). Doll and Hill’s (1950) paper demonstrated the association between smoking
and lung cancer which has become a public health standard. Tobacco use has been reported to be
the main cause of 90% of male and 79% of female lung cancers. Ninety percent of deaths from
lung cancer are estimated to be due to smoking.
The risk of lung cancer development is 20-40 times higher in lifelong smokers compared
to non-smokers (Toraks, 2005). The complexity of tobacco smoke leads to some confusion
about the mechanisms by which it causes lung cancer. Among the multiple components of
tobacco smoke, 20 carcinogens convincingly cause lung tumors in laboratory animals or humans
and are, therefore, likely to be involved in lung cancer induction (Hecht, 1999). Lung cancer is
the leading cause of cancer death in the United States for both men and women (see table 3).
Lung cancer is the most preventable form of cancer death in our society (CDC, 2011). Smoking
can also lead to other health problems, such as, cardiovascular disease.
Table 3 Lung cancer estimates for 2011 (CDC, 2011): www.cancer.org, American Cancer
Society
Male

Female

Total

New Cases of Lung Cancer

115,060

106,070

221,130

Deaths from Lung Cancer

85,600

71,340

156,940
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Smoking and Cardiovascular Disease
The most important behavioral risk factors of heart disease and stroke are unhealthy diet,
physical inactivity and tobacco use. Behavioral risk factors are responsible for about 80% of
coronary heart disease and cerebrovascular disease. Smoking causes coronary heart disease, the
leading cause of death in the United States (USDHEW, 1967). Cigarette smoking causes reduced
circulation by narrowing the blood vessels (arteries) and puts smokers at risk of developing
peripheral vascular disease (i.e., obstruction of the large arteries in the arms and legs that can
cause a range of problems from pain to tissue loss or gangrene) (USDHEW, 1967). Smoking
causes abdominal aortic aneurysm (i.e., a swelling or weakening of the main artery of the body—
the aorta—where it runs through the abdomen) (USDHEW, 1967).
Smoking and the Respiratory Tract and Reproduction
Other health effects of smoking are lung diseases (e.g., emphysema, bronchitis, chronic
airway obstruction) by damaging the airways and alveoli (i.e., small air sacs) of the lungs (CDC,
2011). Smoking has many adverse reproductive and early childhood effects, including increased
risk for—infertility, preterm delivery, stillbirth, low birth weight, and sudden infant death
syndrome (SIDS) (CDC, 2011). One of the ways to decrease the chances of suffering from one
of these health problems is through quitting smoking.
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Addictive Properties and Carcinogens
Quitting smoking cigarettes can be very difficult and one of the main reason why is
because of it’s addictive properties, nicotine. In the 1988 report, The Health Consequences of
Smoking: Nicotine Addiction: A Report of the Surgeon General (U.S. Department of Health and
Human Services, 1988) the pharmacologic basis of tobacco addiction is described as follows:
1. Cigarettes and other forms of tobacco are addicting.
2. Nicotine is the drug in tobacco that causes addiction.
3. The pharmacologic and behavioral processes that determine tobacco addiction are
similar to those that determine addiction to drugs such as heroin and cocaine.
Nicotine addiction is an important element to understand the complexity of quitting. Of
those individuals who have ever tried smoking, about one-third become daily smokers
(USDHHS, 1994). Of those smokers who try to quit, less than 5 percent are successful at any
one time (USDHHS, 2004). Any efforts to reduce tobacco-related disease must take into account
the addiction potential of a tobacco product.
Cigarette smoking is a large health concern in the United States of America. The 2004
Surgeon General’s report, The Health Consequences of Smoking: A Report of the Surgeon
General (USDHHS, 2004), concluded that the evidence is sufficient to infer a causal
relationship between smoking and cancers of the lung, larynx, oral cavity, pharynx, esophagus,
pancreas, bladder, kidney, cervix, and stomach, and acute myeloid leukemia. In addition, the
report found that evidence suggests a causal relationship between smoking and colorectal and
liver cancers. Each puff of each cigarette contains a mixture of thousands of compounds,
including more than 60 well-established carcinogens.
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Measurements of carcinogens or their metabolites in urine, blood, and breath can provide
convenient and reliable quantitative information on human exposure to carcinogens. The
information provided by these measurements allows for an objective evaluation of carcinogen
doses in smokers. These measurements are called biomarkers. Urinary biomarkers are the most
widely applied biomarkers of carcinogen exposure in smokers (Hecht, 2002). Urine samples are
easy to collect in large quantities and isn’t as intrusive or painful as a blood draw. Carcinogens
in cigarette smoke and/or their metabolites are frequently present in large quantities of urine.
Reducing exposure to carcinogens can have positive effects on one’s health. Cigarette smokers
can receive assistance in quitting through smoking cessation programs like cognitive behavioral
therapy.
The Benefits of Smoking Cessation
The negative health effects of cigarette smoking is a major public health concern which
can be reduced through quitting. Quitting smoking has both immediate and long-term positive
effects on a person’s health. According to the Surgeon General, ex-smokers live longer than
people who continue to smoke; quitting smoking also lowers the risk of lung cancer, other forms
of cancer, heart attack, stroke and chronic lung disease. Considering these health effects it is
important to study how smoking cessation treatments help cigarette smokers decrease or quit
smoking (American Cancer Society, 2009). Smoking cessation has major and immediate health
benefits that aid in decreasing the risk of heart attacks, strokes, chronic lung disease and various
cancers including lung cancer (NIH, 2009). The chart summarizes these benefits.

Running Head: Smoking Cessation Treatment

29

Table 4: Benefits that can be reaped from quitting smoking are summarized in the timeline below:

The risk of harm can be decreased or prevented by quitting or decreasing the amount of
cigarettes a person smokes. For this reason many smoking cessation programs and medications
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have been developed to aid smokers in the quitting process. One of the major therapies used in
smoking cessation is cognitive-behavioral therapy (CBT).
Cognitive-behavioral Therapy
Cognitive-behavioral therapy is a form of treatment that focuses on a person’s cognitive,
behavioral and/or emotional processes that may undermine effectively dealing with a particular
problem. The basis of the treatment is recognizing and identifying these maladaptive processes
and problem solve ways to rethink and act on these thoughts, behaviors and/or emotions in a
more positive way. Cognitive-behavioral therapy has been implemented in treatments for
anxiety, eating disorders, depression, abuse, anger, and smoking, among others. Cognitive
behavioral therapy has been well researched which makes it a useful tool for evidence-based
practice (Butler, Chapman, Forman, & Beck, 2006).
The history of cognitive-behavioral therapy can be traced to rational emotive therapy,
rational emotive behavior therapy and cognitive therapy. Rational Emotive Therapy was
developed by Ellis who later changed the name of the treatment to Rational Emotive Behavioral
Therapy as not to negate the importance of behavior in the change process. Ellis believed there
were numerous aspects that affected problem systems including cognitive, emotional, behavioral
and environmental determinants (Ellis, 1993).
With this basis Ellis developed the ABC model which is A= the acting event, B= the
person’s rational or irrational beliefs and C= the emotional, behavioral, and cognitive
consequences. The basis of this therapy is that our beliefs have direct effects on how we feel
(Ellis, 1993). Cognitive Therapy was developed by Beck et al. (1979) for the treatment of
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depression. In cognitive therapy the maladaptive thought process is assumed to be the driving
force towards the disorder or problem.
The foundation of the smoking cessation program in this study is cognitive behavioral
therapy. Participants are taught skills to apply to their day to day activities. Skill sets are taught
instead of just using will power. The counseling program provides a strong supplement to using
the transdermal nicotine patch (reviewed below).
Summary of Counseling Protocol
As mentioned, the theoretical framework for the smoking cessation program is based on
cognitive-behavioral therapy. The smoking cessation program consists of 13 sessions that are
primarily over the phone. The counseling sessions vary from 15 minutes to 60 minutes
depending on the session. The timing of the sessions is held to a strict schedule as the smoking
cessation program is part of a research study.
Pre-Quit Session
The Pre-Quit Session is a 60 minute group session. The session begins with a welcome to
the participants to congratulate them for joining the program and attempting to quit smoking.
The counselor introduces him or herself by briefly sharing their education and work related
experience. After the congratulations and the counselor’s introduction, the participant’s
responsibility is reviewed (i.e., completing questionnaires and taking medications correctly). A
study overview is discussed so participants are aware of what takes place at each session. The
nicotine patch is discussed in terms of storage, proper use and possible side effects.
After the study procedures are fully discussed, participants are given an opportunity to
discuss their own experiences in more detail. Each group member gives a brief introduction
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about who they are and what led them to the program. They also respond to questions about
their smoking experience.
Questions such as the following are asked:
1. How did you come to the decision to quit?
2. How long have you been smoking?
3. How much do you currently smoke?
4. Have you ever tried to quit?
5. What was your longest smoke-free period?
6. What strategies helped you remain smoke –free during that period?
7. What strategies did not seem to help?
8. How did you end up smoking again (where, when, who was there)?
9. Did you try to quit again immediately after that?
10. Are there any obstacles for you in quitting, such as concerns about weight gain or
coping without cigarettes?
11. How much do you want to quit?
12. How confident are you that you could quit for good?
After the participant introductions the counselor begins to discuss what led the participant
to wanting to quit. Participants are asked to list reasons why they want to quit. The counselor
then asks the participants to share their responses and each response is grouped into physical
benefits, social benefits and psychological benefits. Participants are given a visual of the many
positive aspects of quitting, including the physical benefits such as a reduction to many illnesses,
social benefits such as not having to sit in smoking sections, and psychological benefits such as
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not having to worry about purchasing cigarettes or feeling guilty or self-conscious because you
smoke.
The counselor then begins to explain the cycle of addiction. The physical component as
well as the behavioral component is discussed. The physical component discusses nicotine and
the addiction. The behavioral component discusses the habit of cigarette smoking. The
discussion of habits leads to participants starting to think about and list triggers. Participants are
then given wrap sheets. They are called wrap sheets because you can fold it around your
cigarette box. The rap sheet includes a section to write down the time you lit your cigarette,
what you were doing at the time you had your cigarette and how you were feeling (happy, sad,
depressed).
Next the participants are given skills on how to manage their triggers. The technique is
called avoid, alter or substitute. For instance, if the participant’s trigger is coffee then the
participant could avoid by not drinking coffee, alter by drinking coffee to go instead of in the
kitchen (which is an altering of location), or substitute by drinking tea instead of coffee. These
strategies along with medication are revisited at each follow-up session.
Strengths of CBT Components in Counseling Protocol
The smoking cessation program has many basic components of cognitive-behavioral
therapy. The overall structure of the counseling explores dynamics of smoking including the
physical addiction, the habit or behavior, and what led the person to light a cigarette. The study
makes an assumption that the participant is able to distinguish the feelings, emotions, thoughts
and behaviors that are attached to their trigger. The thought process is the first step in coming up
with a plan to stop smoking. This is a basic principle of cognitive-behavioral therapy.
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Another element of CBT that is evident in the protocol is educating participants about
their triggers. Understanding triggers makes the participant aware of their thought process and
behaviors attached to cigarette smoking. This concept is made more concrete with the use of
wrap sheets. The wrap sheets make the participant look at their habit of smoking more careful
(Ellis, 1993).
Participants are asked to complete the form every time they light up a cigarette. The
wrap sheets allow the participants to discover or unveil their own particular behavior of smoking.
For example, asking the participant what they were doing when they lit their cigarette and what
time it was when they began smoking, is an exploration of their thought process and emotions.
By having the participants circle how they feel allows the participant to think about the emotions
that may be attached to their smoking and what they were thinking about before they started
smoking. Another CBT component is in the introduction; the participants are asked to explain a
little bit about their smoking history and their past quit attempts.
Cognitive-behavioral therapy is conducive for research settings because it’s brief and
highly structured. Researchers have to make sure all the participants are given the same amount
of information in the same amount of time. CBT makes it easier for the counselor to stay on
track because of the tangible assignments. Many sessions are over the phone instead of inperson because this study is an effectiveness trial and therefore the protocol was designed to be
as close to real-life as possible versus a more carefully controlled trial (i.e. efficacy trial). This
study incorporates a CBT model for a smoking cessation program; however, CBT alone is not as
effective treatment as CBT when coupled with a medication. Several studies have shown the
effectiveness of CBT along with a medication is enhanced.
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Cognitive-behavioral Therapy in Conjunction with Medications
Only about 4 to 7% of people are able to quit smoking on any given attempt without
medicines or other help incentives (average across attempts). Quitting smoking can be
challenging but there are many programs available to assist smokers. Some of these programs are
telephone and in-person counseling, psychoeducational and cognitive behavioral therapy. Also
pharmacological treatment has been found to be an effective source of assistance.
Several research studies have looked into the use of CBT for smoking cessation.
Cigarette smokers often have other mental health disorders such as depression. For this reason
CBT can be very helpful because it is commonly used for those suffering from depression and
for cigarette smokers. In the Hall et al. (1996) study the counselors used a CBT model for
smoking cessation treatment with cigarette smokers who have a history of major depressive
disorder (MDD). Participants were also given the nicotine gum. Mood management was
completed in 10 group sessions over 8 weeks and standard treatment was given in 5 group
sessions. The cognitive-behavioral intervention increased the amount of participants with Major
Depressive Disorder who were abstinent. Those with past MDD had the greatest abstinence
rates.
In Evins (2001) study, bupropion was used in conjunction with cognitive-behavioral
therapy (CBT) to treat the smoking behavior and for stabilizing psychiatric symptoms in patients
with schizophrenia. The study consisted of a 3-month, double blinded, placebo-controlled trial.
Those in the active drug group had an improvement in negative symptoms and greater stability
of psychotic and depressive symptoms. Those in the active group also had significant weight
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loss. The study suggests that bupropion combined with cognitive-behavioral therapy may
facilitate smoking reduction in cigarette smokers with schizophrenia.
Other studies have looked at the correlation between major depressive disorder and
smoking cessation. Notriptyline is another drug that appears promising when coupled with CBT
to help those wanting to quit who also suffer from MDD (Hall et al., 1998). In the Hall and
colleagues (1998) study they replicated that MDD history-positive participants are helped by the
10-session cognitive-behavioral treatment. Also there was a correlation between serum levels
and abstinence which suggests the medication was helpful. These studies show the success of
CBT which is often coupled with a medication. For this study CBT was used in conjunction
with transdermal nicotine patch. In this review of CBT for smoking cessation the selected
studies often had psychiatric patients, the research is limited for the general population and for
this reason the most related studies were selected.
Nicotine Patch
Nicotine replacement therapy (NRT) increases smoking cessation rates significantly vs.
placebo or counseling alone (Fiore et al., 2008; Schnoll & Lerman, 2006). Nicotine gum is often
used improperly and is not effective across all settings (Cepeda-Benita et al., 1993). Nicotine
nasal spray and inhaler can be aversive, lowering compliance rates vs. other NRTs (Kaufmann et
al., 2004; West et al., 2001). While there are data to support the use of the nicotine lozenge, the
2008 PHS treatment guideline concluded that the scientific support for this NRT is limited (Fiore
et al., 2008). Relative to these NRTs, transdermal nicotine (nicotine patch) has the fewest side
effects and yields the highest compliance rates. As a consequence, the transdermal nicotine patch
is the most widely used form of tobacco dependence treatment in the US (Jonk et al., 2005;
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Pierce & Gilpin, 2002) and Europe (Tilson, Bennett, & Barry, 2004; West et al., 2005). The
transdermal nicotine patch is also available over-the-counter (OTC), allowing for new
recommendations concerning its use to be easily disseminated and adopted.
A meta-analysis of 40 placebo-controlled clinical trials of transdermal nicotine (Stead et
al., 2008) and the recent PHS guideline (Fiore et al., 2008) concluded that transdermal nicotine
increases the odds of cessation vs. placebo by ~70%. However, only ~20% of smokers are able
to maintain abstinence for 6 months following patch treatment (Fiore et al., 2008; Stead et al.,
2008) even when patches are accessed OTC (Pierce & Gilpin, 2002). At 12-months, only ~9% of
individuals who use transdermal nicotine are abstinent (Russell et al., 1993; Imperial Cancer
Research Fund General Practice Group, 1993). At 6-months, the efficacy of standard therapy
with transdermal nicotine is comparable to bupropion (Hughes, Stead, & Lancaster, 2007), but
lower than the new nicotinic receptor partial agonist medication, varenicline, which produces 6month quit rates of ~35% (Cahill, Stead, & Lancaster, 2007; Gonzalez et al., 2006; Jorenby et
al., 2006). Bupropion and varenicline, however, can yield side effects and have numerous
medical contraindications that limit who can use these treatments (Schnoll & Lerman, 2006). For
instance, the Federal Aviation Administration and the Federal Motor Carrier Safety
Administration have recently added varenicline to their list of drugs that should not be used by
pilots or truck drivers.
Age and Gender
Research has shown that the success of smoking cessation treatment can be greatly
affected and produce differing outcomes based on associated factors, such as, age and gender. In
the McWhorter, Boyd, and Mattson (1990) study, independent predictors of quitting were: (1)
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older age; (2) White race; (3) fewer cigarettes smoked/day; (4) higher household income; and (5)
hospitalization in the follow-up period. Predictors of relapse were: (1) younger age; (2) urban
residence; and (3) female gender.
According to Dietz, Sly, Arheart, and McClure (2010) young adults (18-24 years) have
the highest smoking rate of any age group. They studied 4401 young adults using telephone
interviews as part of the evaluation for the Tobacco Free Florida Campaign. The study
researched which factors influenced young adult cigarette smokers with a focus on lifestyle,
tobacco use tolerance, and attitude/beliefs. The study found that 20.3% of the young adults
smoked cigarettes, males were more likely to be smokers at a prevalence rate of 25.1% than
females with a smoking prevalence of was 15.6%. Non-Hispanic Whites were more likely to be
smokers than other racial/ethnic groups at a prevalence rate of 23.8%. The findings suggested
that as young adults reject negative labels attached to smokers, they are more likely to smoke.
Similar studies in other countries have looked socio-demographic descriptors as they
relate to smoking and smoking cessation. Kaleta, Korytkowski, MAkowiec-D Browska,
Usidame, B K-Romaniszyn, and Fronczak (2012) collected data on a representative sample of
7,840 individuals including 1,206 individuals who met the criteria of long-term smoking
cessation and 2,233 current smokers. The data was collected through the Global Adult Tobacco
Survey (GATS). Smoking cessation rate was calculated as calculated as the number of former
smokers divided by the number of ever smokers. The study found that the quit rate for women
was 30.4% and for men was 37.9%. Older age, high education attainment, awareness of
smoking health consequences was associated with long-term quitting among genders (Kaleta
et.al., 2012).
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In the Osler and Prescott (1998) study, quitting smoking was positively associated with
male sex and cigar smoking and negatively associated with the amount of tobacco smoked,
inhalation, and alcohol consumption. Furthermore, in women, smoking cessation was positively
associated with level of education and body mass index (BMI). These studies suggest that age
and gender can be a predictor of quitting. Due to the effects of age and gender or cigarette
smokers these two elements will be control variables in the proposed research study.
Summary and Research Question
Studies have shown that cognitive-behavioral therapy and the nicotine patch have been
effective resources for quitting smoking. Preliminary data has shown that spirituality can aid in
the success of addiction treatment programs and positively affect a quit attempt in a smoking
cessation program. Interest in including spirituality in a smoking cessation program has also
been assessed. These studies led to the proposed research question. Specifically, among
cigarette smokers participating in a nicotine patch smoking cessation program, to what extent
does the level of spiritual well-being explain success (defined as abstinence at the 8 week point)
of a smoking cessation program when controlling for age and gender?
The proposed research study can be a catalyst for determining whether spirituality should
play a part in smoking cessation programs. The research findings can build on the concept of
adding a spiritual piece to future programming. Participants in the smoking cessation program
will complete the Spiritual Well-Being Scale (Paloutzian & Ellison, 1982) at the initial baseline
session before treatment. Data will be analyzed to see if levels of spiritual well-being in any way
relate to cigarette smokers probability of quitting smoking. The analysis from the proposed study
will help guide further addiction research and smoking cessation programs by providing an
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additional method for participants to explore during the quitting process. If spiritual well-being is
related to quitting, smoking cessation programs can be structured to give counselors diverse
skills to equip potential quitters with the knowledge they need to avoid or decrease the chance of
harmful effects from smoking. The study hypotheses are:
1. Cigarette smokers with higher levels of spiritual well-being who participate in a
smoking cessation program are more likely to quit smoking when controlling for age
and gender.
2. Cigarette smokers with higher levels of spiritual well-being will be less likely to drop
out of the treatment program when controlling for age and gender.
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Chapter 3: Research Design and Methods
Study Population
A sample of 178 cigarette smokers was included in the proposed study, Understanding
the Role of Spiritual Well-Being in a Smoking Cessation Program, to assess the relationship
between levels of spiritual well-being and abstinence after an 8-week behavioral counseling and
nicotine patch smoking cessation treatment program. The study was conducted through two large
city university sites (the University of Pennsylvania and Northwestern University) with extensive
experience conducting smoking cessation studies. As was done for previous smoking cessation
studies at this center, recruitment consisted of media ads (newspaper, radio) as the main form for
recruitment, as well as, flyers.
The proposed study was completed in conjunction with an existing study, Dr. Robert
Schnoll’s, An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence, study. The
proposed study involved the inclusion of a spirituality measure at the baseline session. The
research design and methods section will focus on just the portions of Dr. Schnoll’s study that is
needed for the purpose of this study, Understanding the Role of Spiritual Well-Being in a
Smoking Cessation Program. Dr. Schnoll’s study involves randomization to either 8-weeks, 24weeks, or 52-weeks of behavioral and nicotine patch treatment. To eliminate the potential effect
of treatment duration, my assessment of whether a participant is quit or not occurred at the 8week mark when all participants were still using the patch.
Research Design
This was a longitudinal study and the baseline Spiritual Well Being scale was used to
determine if spiritual well-being was a predictor of abstinence at the 8 week mark amongst 178
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community smokers from Philadelphia (UPENN) and Chicago (Northwestern University)
participating in a combined CBT and transdermal nicotine patch treatment study. Subjects
received the 21mg transdermal nicotine patch for 8 weeks along with CBT-based smoking
cessation counseling.
Individuals contacting the recruitment line were initially screened for eligibility by
phone. Those eligible were scheduled for an intake session, where eligibility was confirmed.
Those eligible at the intake session and interested in the trial completed informed consent forms,
the HIPAA documents, and the baseline measures, which included the Spiritual Well-Being
Scale (Week -2). At week -1, participants received their patches, a single in-person counseling
session (a pre-quit session), and set a target quit date (TQD) for one week later (Week 0). At
Week 0, all participants received a second counseling session by phone and began the 21mg
transdermal nicotine patch treatment. During the subsequent weeks, participants received two
additional counseling sessions by phone (10-15 minutes each), and completed study measures.
Participants who self-reported abstinence during the 7 days prior to the outcome measure timepoint were asked to attend the site to provide a breath sample for biochemical verification. The
primary outcome was the 7-day point prevalence abstinence at week 8 (self-reported abstinence
for 7 days prior to the assessment and carbon monoxide [CO] of < 10ppm). Those who did not
complete this assessment were considered to be smokers, based on the intent-to-treat model.
Study Procedures
Intake Session (Week -2)
Participants were scheduled to meet the Study Coordinator for an intake session at the
respective site. At this intake session, the participant’s eligibility was confirmed with a medical
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history and a physical exam (including a pregnancy test for women). If eligible and willing to
proceed, the participant completed informed consent and HIPAA documents and were officially
registered on the study. Hard copies of eligibility screening data and consent/HIPAA forms were
stored in a subject’s study binder. Eligibility data were entered into the web-based Data
Management System used successfully in our previous multi-site smoking cessation clinical
trials (Schnoll et al., 2010).
During the Intake Session, the Study Coordinator completed a baseline assessment. This
assessment collected data on smoking history, demographics, depression, baseline smoking
rate/behavior (including CO) and spiritual well-being. All baseline data were collected on Case
Report Forms (CRFs) devised for this study and was stored in the participant’s study binder.
Once the baseline data collection was complete, the participant initiated treatment.
Behavioral Counseling Sessions (Week -2 to Week 8)
All subjects received a manual-based intervention from a trained smoking cessation
counselor from Week -2 to Week 8. Behavioral counseling was included given its’ demonstrated
efficacy at helping smokers quit (Fiore et al., 2008) and to increase compliance with procedures
and retention. Phone counseling was selected for all sessions (except the initial session) since it
has demonstrated clinical and cost-effectiveness and can increase compliance and external
validity (Fiore et al., 2008; Hollis et al., 2007; Stead et al., 2007). Since all study participants can
access telephone counseling through the Pennsylvania and Illinois quit-lines, use of telephone
counseling in this trial is consistent with community-based practice and an effectiveness trial.
The counseling program began with a 1-hour in-person individual counseling session to prepare
for the target quit day (Week -2); at the next session, participants will receive a 30-minute “quit-
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day” session by phone to prepare for quitting (Week 0). Lastly, participants received 15-minute
booster sessions by phone at Weeks 4 and 8. The counseling program was designed to enhance
awareness of the harmful effects of smoking, assist the person in developing skills to quit and
avoid relapse, and instruct the smoker on NRT use. Compliance with patch use recommendations
was emphasized. A random 25% of sessions were audio-taped and assessed for protocol
adherence. An experienced and trained counselor at each site conducted all sessions and will not
conduct any assessments.
Pre-Quit Session (Week -2; 1-hour)
At the pre-quit visit, subjects received introductory materials (e.g., program overview and
logistics) and materials to help them prepare for their quit date. A quit day for Week 0 was
selected. Support and encouragement was provided by the counseling staff. The counselor
reviewed the personal risks of continuing to smoke (e.g., cancer) and provided a quit plan.
Specific strategies were described: 1) gradual reduction before quit day (i.e., scheduled
smoking); 2) self-talk of reasons for quitting; 3) enlisting support of friends and family; 4)
awareness of tempting situations and the need to avoid them or create a plan for using
alternatives (e.g., distraction); and 5) removing smoking cues. A tip sheet of strategies was
given.
Quit Day Session (Week 0; 30 Minutes)
This session focused on nicotine patch use and strategies to manage withdrawal and
avoid relapse. Subjects were urged to maintain awareness of tempting situations (e.g., being
around smokers) and to develop a repertoire of alternatives to cope with dangerous situations.
Other skills for avoiding relapse that were discussed and encouraged: developing an exercise
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regimen, relying on the support of friends and family, reminding oneself of the reasons for
quitting, and use of self-distraction and reinforcement. These techniques helped avoid relapse
(Anderson & Wetter, 1997; Fiore, Jorenby, & Baker, 1997). The counselor reviewed NRT use
and clarified concerns that subjects may have.
Relapse Prevention Sessions (Weeks 4 and 8)
These “booster” sessions focused on relapse prevention. Previous session material was
reviewed and successes or failures were assessed. The Session 1 quit plan was either revised or
reinforced depending on the degree of progress. Problem-solving was a central component to
these sessions; the counselor had participants identify tempting situations (i.e., when slips
occurred or cravings high). New concerns about sustained abstinence were probed (e.g., fear of
stress reactions or weight gain) and strategies for managing these issues were discussed.
Transdermal Nicotine Treatment
During the Pre-Quit counseling session, the counselor reviewed the purpose of using the
nicotine patch (e.g., to help manage withdrawal symptoms; not a substitute for behavioral
quitting strategies), provided directions on how to use the patch (e.g., abstinence from smoking,
patch location, time, activity, and potential skin reactions), and answered any questions. The
supply of transdermal patches for the study was distributed at this point. Participants were
instructed to promptly discontinue the patch and contact the respective study coordinator if they
experienced severe or persistent local skin reactions (e.g., severe redness, itching, or swelling) at
the site of patch application or a generalized skin reaction (e.g., raised patches, hives, or
generalized rash). Any serious adverse reactions or significant side effects of transdermal
nicotine were evaluated by a physician at the respective site. Patch use by such individuals was
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monitored and adjusted as needed. Based on previous and ongoing experience with nicotine
patch studies at the UPENN site (e.g., Lerman et al., 2004; Schnoll et al., 2008), few serious
adverse events were expected. Data from any subject experiencing adverse effects (even if
requiring discontinuation of medication) was analyzed based on an intent-to-treat model.
Consistent with the lack of evidence for a difference in effect with tapering (e.g. 4 weeks 21mg,
2 weeks 14mg, 2 weeks 7mg) versus no tapering, all participants received the 21mg dose
throughout the treatment phase.
Mid-treatment Assessments
After the baseline assessment at Week -2, assessments were conducted during the clinical
trial at Weeks 0, 4, and 8. These assessments were conducted by a trained and experienced
Research Assistant (not the counselor) and were completed over the telephone following the
counseling session. These assessments required only about 15 minutes to complete. Assessments
included measures of treatment side-effects, adherence to patch use and smoking behavior.
Outcome Assessments
The primary outcome variable was 7-day point prevalence abstinence at Week 8,
biochemically-confirmed with CO. All data were collected by telephone by a trained and
experienced Research Assistant. Participants reporting abstinence for the 7-days prior to Week 8
were asked to attend the respective clinic to provide a CO sample. Costs for transportation and
financial incentives were provided to increase compliance with this requested visit.
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Table 5 Measures/Events
Week

-2

0

4

8

X

X

X

X

X

X

X

X

X

X

X

X

X

X

TREATMENT
Standard Transdermal Nicotine
Counseling

X

SCREENING/COVARIATES
Demographics

X

Smoking history/FTND

X

Medical history

X

Spiritual Well-Being Scale

X

TREATMENT VARIABLES
Adherence/Usage
Side effects
OUTCOMES
Cessation/smoking rate (CO@ wk 8) X
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Setting
University of Pennsylvania Tobacco Use Research Center (TURC)
The PENN Tobacco Use Research Center (TURC), which began in 1999, is an
NCI/NIDA-funded center devoted to the evaluation of treatments for nicotine dependence (PI:
Dr. Caryn Lerman). The TURC is part of the Department of Psychiatry at the PENN School of
Medicine but it is located off-campus, in a community office building within the downtown city
of Philadelphia. The TURC has been the treatment facility used to support several large clinical
trials, small pilot projects, post-doctoral fellows, and core trial facilities (e.g., Lerman et al.,
2004, 2006; Schnoll et al., 2008).. The UPENN TURC provides the necessary infrastructure for
this trial. The TURC encompasses 6,500 square feet, including space for faculty and staff offices,
conference rooms, clinic rooms for treatment and assessment, several small laboratory rooms for
biological assessments and storage, and data storage facilities (paper and computer). The efficacy
trial of extended transdermal nicotine treatment was conducted through the UPENN TURC.
Northwestern University Behavioral Medicine Program
The Northwestern University Department of Preventative Medicine is part of the
university’s School of Medicine and is comprised of faculty and staff devoted to teaching and
research. In addition to preparing students to address disease prevention and control, improve
access to and quality of health care, and better organize and finance health care services, the
Department of Preventative Medicine supports leading-edge research into numerous medical
conditions, including behavioral science and addictions research. The Department of Preventive
Medicine is home to several nationally and internationally renowned landmark collaborative
studies, including the Women's Health Initiative (WHI). Within this Department, the Behavioral
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Medicine Program is a clinical and research unit that uses a multidisciplinary approach to
understanding, preventing, and treating disease. Researchers with backgrounds in clinical
psychology, kinesiology, nutrition, public health, nursing and medicine conduct grant-funded
projects to understand the influences of psychological, socio-cultural, and biological factors on
health. Behavioral Medicine faculty specialize in the development and implementation of
behavioral interventions to promote health, including the evaluation of treatments for nicotine
dependence. The Behavioral Medicine Program is located in downtown Chicago with convenient
access to city residents. The Behavioral Medicine Program is comprised of 25,243 sq. feet of
office space, including suites for faculty and administrative personnel, consulting rooms and
meeting rooms for participant assessment and data collection, laboratory suites for the collection
and storage of biological data, and data management and storage facilities.
Sample Size and Recruitment Procedures
Based on previous studies researching spirituality, the proposed study sample consisted
of 178 adult (>18 years of age), female and male cigarette smokers who were interested in
entering into a smoking cessation program. With a sample of 178 and alpha of .05, power of .80
requires an odds ratio of 1.559 or greater. The study utilized a sample of cigarette smokers who
were voluntarily interested in a smoking cessation program. From previous studies at the center
we expected that about 12 participants would complete the measure each month and with this
understanding we expected the study to take 15 active recruitment months.
As was done for previous smoking cessation studies at this center (Schnoll et al., in 2008;
Spring et al., 2007), we utilized media ads (newspaper, radio) as the main form of recruitment.
We utilized media sources with large African American and Hispanic-American readership or
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listenership as well as media sources with young adult audiences. This method of recruitment,
though expensive, has allowed this research group to ascertain large (i.e., >500) and diverse (i.e.,
>30% racial/ethnic minority) study samples in their clinical trials. As a secondary form of
recruitment, we distributed posters and flyers advertising the study to medical clinics across the
UPENN and Northwestern-affiliated hospitals. The ads and flyers included instructions for
enrollment and a toll-free phone number for participants to call to enroll in the study. A Research
Assistant at the sites screened incoming calls from prospective participants for basic eligibility
(e.g., number of cigarettes/day) and study interest.
Study Inclusion Criteria
1) Males and females over age 18 who smoke at least 10 cigarettes/day.
2) Able to communicate in English.
3) Able to use the transdermal nicotine patch safely (e.g., no allergy to latex).
4) Able to provide written informed consent for study procedures.
Study Exclusion Criteria
1) Are unable to communicate in English.
2) Have a current medical condition that would make using transdermal nicotine patch unsafe
(e.g., allergy to latex);
3) Pregnant or planning to become pregnant or lactating.
4) Participants with asthma, diabetes, hypertension, or heart disease (e.g., coronary artery
disease, abnormal heart rhythm, an arrhythmia) will be permitted to enroll in the study with
medical clearance from the participant’s physician.
Retention
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Both sites have extensive experience with retaining study participants in clinical trials
and maintaining compliance with study protocols. First, in terms of retention of study
participants, in our efficacy trial of extended transdermal nicotine, less than 10% of participants
withdrew from the study (Schnoll et al., 2010). Further, our rates of assessment completion at
week 8 were 74%. For the Northwestern University fluoxetine trial, 31% of participants
withdrew from the trial (Spring et al. ?); this rate is higher than we expect in the proposed study,
since this trial included intensive in-person group therapy and 10% of withdrawals were due to
drug side-effects. The assessment completion rate approached 67%, which compares favorably
to large smoking cessation randomized trials (e.g., Jorenby et al., 1999; Gonzales et al., 2006).
To ensure a high level of retention and compliance in this trial we: 1) educated subjects
about the benefits of complying with the protocol; 2) used phone counseling and assessments and
require only abstinent subjects at week 8 to attend clinic; 3) scheduled in-person sessions at
times convenient for the subject, including evening and weekends; 3) maintained close contact to
meet subjects’ needs; and 4) as is standard practice in smoking cessation trials (Hall et al., 2004;
Niaura et al., 2005), provided financial incentives for completion of sessions. As is advised in
smoking cessation clinical trials (Hughes et al., 2003), we utilized intent-to-treat (completed
orientation, baseline and pre-quit visit) for primary analyses, which assumes that missing
outcome data are coded as smokers.
Subject Payments, Tracking Procedures
Participants were provided compensation but it was not substantial enough to provide
undue inducement to participate in the research. Rather, the compensation was meant to show
appreciation for the completion of study measures and/or travel to the treatment site for study-
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related responsibilities. There were 3 time-points for which we provided reimbursements. We
provided $20.00 for each time-point for which assessments were complete (weeks 0, 4, 8).
Data on Refusers and Drop-outs
Any data collected on drop-outs was analyzed. Drop-outs were included as smokers in
the study. Attendance was tracked by Research Assistants who recorded study participation in
the research database.
Measures
Demographics and Smoking History Assessment
Standard surveys collected: demographics (e.g., age, gender, and ethnicity) and smoking
history (e.g., age at initiation, prior abstinence periods, past use of nicotine treatments, current
rate).
Abstinence (primary outcome)
Smoking status was assessed and biochemically verified (saliva sample). A standard
timeline follow-back method (Brown, Burgess, Sales, & Whiteley, 1998) was used, as was done
previous studies at the Transdisciplinary Tobacco Use Research Center (Lerman, Kaufmann et
al., 2004). Participants who reported complete abstinence (not even a puff of a cigarette) for at
least the 7 days prior to the assessment at week 8 were asked to complete an in-person visit for
biochemical verification of abstinence. The primary outcome was biochemically verified 7-day
point prevalence at 8 weeks. As per convention, participants assumed to be smoking if they selfreport to be smoking, could not be reached to provide data, failed to provide a CO sample or
provide a CO sample at week 8 that is > 10ppm (SRNT Subcommittee on Biochemical
Verification, 2002).
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Biochemical Verification
Self-reports of smoking cessation during treatment and at the end of the treatment phase
were verified using carbon monoxide (CO) with a cutoff of 10ppm. Subjects reporting
abstinence, but exhibiting CO levels above threshold, were treated as smokers in the analysis (for
the sessions in which CO was taken) (SRNT, 2002).
Spiritual Well-Being
Spirituality or spiritual well-being was defined as a sense of relatedness or connectedness
to others, a provision for meaning and purpose in life, the fostering of well-being (through a
stress buffering effect), and having a belief in and a relationship with a power higher than self
(Hawks et. al., 1995). Spiritual Well-Being was measured with the administration of the Spiritual
Well-Being Scale (SWBS).
The Spiritual Well-Being (SWB) Scale is a 20-item self-report assessment instrument
which is intended to measure people’s overall SWB as it is perceived by them in both a religious
well-being sense and an existential well-being sense. The measure is constructed of these two
subscales, one that represents religious well-being (RWB) and one that represents existential
well-being (EWB). Each subscale contains 10 items. All of the RWB items contain the word
“God.” The EWB items contain no specifically religious language, instead asking about such
things as life purpose, satisfaction, and relations with the people and situations around us.
Each item is rated on a 6-point Likert Scale with answer options ranging from “strongly agree”
to “strongly disagree,” with no midpoint. The items are scored from 1 to 6, with a higher
number representing more well-being. These scores are summed in order to yield three scale
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scores; one score for RWB, one score for EWB, and one score for total SWB. RWB and EWB
scores can range from 10 to 60. SWB total scores can range from 20 to 120.
Reliability
Test and re-test reliability coefficients for four different samples with 1, 4, 6, and 10
weeks between testings ranged from .88 to .99 for RWB, .73 to .98 for EWB, and .82 to .99 for
SWB. The internal consistency reliability coefficients, based on data from over 900 subjects
across seven studies, ranged from .82 to .94 for RWB, .78 to .86 for EWB, and .89 to .94 for
SWB. These data indicate high internal consistency and reliability (Paloutizian & Ellison, 1982).
Validity
The SWB scale appears to measure what is intended. Face validity is evident by
examination of the content of the items. Also, the authors report a factor analysis of the items,
whose results yield factors that correspond to the two subscales (Paloutizian & Ellison, 1982).
The RWB items cluster strongly together on one factor. The EWB items tend to cluster together
on two subfactors that connote life direction and satisfaction. These results are generally
consistent with the conceptual structure guiding the development of the scale. Some subsequent
research may suggest a more complex factor structure (Ledbetter et al., 1991).
Validity is also indicated by correlations between the SWB scale and other measures with
which it ought to be associated on theoretical grounds. For example, people who scored high on
SWB scored lower on loneliness, higher on self-confidence, and higher on intrinsic religious
orientation. The SWB, RWB, and EWB scores were all positively correlated with a sense of
purpose in life (Paloutizian & Ellison, 1982).
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Populations (from other studies)
The original sample consisted of 206 students from Biola College, Westmont College,
Pepperdine University, and the University of Idaho. Various initial studies employed over 500
subjects, including men and women (married and single), college and high school students,
senior citizens, religious and non-religious people, and people from large cities, small towns, and
rural areas. Subsequent research has included a wide variety of sample including people with
AIDS, terminal cancer patients, nurses, sociopathic convicts, medical outpatients, outpatient
counselees, people with eating disorders, sexually abused outpatients, and people in several
Christian denominations (Hill & Hood, 1999).
Training of data collectors
I reviewed the Spiritual Well-Being Scale with Dr. Robert Schnoll, the Principal
Investigator of the overarching study along with the Project Manager. Kia Kerrin met with
Robert Schnoll’s staff to explain why the measures were added and the proper way to complete
the forms. The Project Manager followed-up with the research assistants on the proper way to
complete the form.
Data Analysis
The hypothesis was that “cigarette smokers who participate in a smoking cessation
program with higher levels of spiritual well-being are more likely to be quit at the 8 week mark
and more likely to still be attending the program.” Levels of spiritual well-being were measured
by the scores from the SWB scale. The statistical analyses were based on binary abstinence (vs.
smoking) at the 8-week point of the study. Abstinence was defined as biochemically-confirmed
7-day point prevalence. A logistic regression model was estimated to identify predictors of
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abstinence. Other variables were included as covariates such as demographics (race, gender, age,
amount of cigarettes smoked per day). Categories that had single observations (i.e. race) were
collapsed into one group for analysis.
Administrative Arrangements
Dr. Robert Schnoll, the Principal Investigator, of the smoking cessation study had agreed
to include the Spiritual Well-Being Scale into his curren/t baseline study measures packet. The
Spiritual Well-Being Scale was approved by the IRB to be included in the study. The measures
were entered in an Access database.
Human Subjects
The measures for the study, Understanding the Role of Spiritual Well-Being in a Smoking
Cessation Program, were supplements to the currently enrolling smoking cessation study, An
Effectiveness Trial of Maintenance Therapy for Nicotine Dependence. The University of
Pennsylvania Institutional Review Board approved all procedures for the smoking cessation
study, An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence (protocol
number: 809140). A copy of the measures was submitted with a cover letter stating the time
point in which the measures were administered. The Spiritual Well-being Scale was an
addendum to the existing measures packets at the Baseline Session. Study measures were
included in the packets upon approval of the University of Pennsylvania’s Institutional Review
Board. Participants also completed a HIPPA privacy rights form.
Several steps were taken to keep all data confidential. All participants were assigned an
identification number. Data were reviewed and analyzed using this numeric system. No personal
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information was sent via email. Hard copy measures were saved in a chart and locked in a file
cabinet. Data entered was saved in a secured computer password assessed database.
No data were collected without the participant’s written informed consent. Each
participant had the study objectives and the type of data to be collected in this trial clearly
explained to them before the study initiation. Separate consent was obtained for the audio-taping
and video-taping. Participants could decline to provide consent for video and audio taping and
still enroll in this trial (they will not be video or audio-taped). Data may only be disclosed to
entities that required disclosure of information to (e.g., PENN and Northwestern IRB, NIH). All
data were stored in locked file cabinets and password protected electronic databases. A database
manager at UPENN was responsible for database security.
Paper-based records were kept in a secure location and only were accessible to personnel
involved in the study. Computer-based files were only made available to personnel involved in
the study through the use of access privileges and passwords. Whenever feasible, identifiers
were removed from study-related information. Precautions were in place to ensure the data were
secure by using passwords and encryption, because the research involves web-based surveys.
Audio and/or video recordings were transcribed and then destroyed to eliminate audible
identification of subjects.
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Chapter 4: Results
General Analysis
The sample for this analysis included 178 participants of which 91 were male and 87 were
female. The mean age was 46 years old with the youngest participant being 20 years old and the
oldest being 70 years old with a standard deviation of 11.93. The racial breakdown of the
participants was 3 Asian, 82 Black or African-American, 90 White, 1 more than one race, 2
unknown or not reported. The educational breakdown of the participants were 1 completed grade
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school, 10 completed some high school, 35 completed high school or GED, 83 completed some
college or technical school and 49 completed college or beyond. Participant’s marital status
were 76 never married, 31 married, 52 divorced or separated, 3 widowed and 16 marriage-like
relationship. See table 6 for all characteristics of participants.
Participants smoking data were as follows: cigarettes smoked per day (cpd) ranged from 6 to
70 with the mean being around 17. Participants’ Fagerstrom Test for Nicotine Dependence
(FTND) score ranged from 0 to 10 with the mean being around 5. The overall Spiritual Wellbeing scoring ranged from 20 to 104 with the mean being 47. When the scale was broken down
into the subset scales the scores for religious well-being (RWB) ranged from 10 to 60 with a
mean of 25; the existential well-being (EWB) scores ranged from 10 to 46 with a mean of 21.

Table 6: Characteristics of Participants (N = 178)
Variable
Sex
Male
Female
Race
Black
White
Asian
More than one race
Unknown or Not Reported

N or Mean

% or SD

91
87

51.12
48.88

82
90
3
1
2

46.07
50.56
1.69
.56
1.12
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Marital Status
Never Married
Married
Divorced or Separated
Marriage – Like Relationship
Widowed
Education
Grade School
Some High school
High School Graduate or GED
Some College or Technical School
College Graduate or Beyond

Age
Variable
Cigarettes per day
SWB
RWB
EWB

60

76
31
52
16
3

42.70
17.42
29.21
8.99
1.69

1
10
35
83
49

0.56
5.62
19.66
46.63
27.53

45.7

11.929

N or Mean

% or SD

17.48

8.05

47.37

18.80

25.65

13.54

21.72

8.86

Preliminary Data Analysis
A one way ANOVA test the relationship between SWB and EWB and potential covariates
(e.g., age, gender) as well as the relationship between 8-week abstinence and potential
covariates. Categories that had single observations (i.e. race) were collapsed into one group for
analysis. The ANOVA tests whether the means of a population are the same (your null
hypothesis) or if they differ between populations (your research hypothesis) by looking at the
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variances. A one-way analysis of variance (ANOVA) is used if there is a categorical independent
variable (with two or more categories) and a normally distributed dependent variable and you
wish to test for differences in the means of the dependent variable broken down by the levels of
the independent variable. Bartlett's test is used to test whether samples are from populations with
equal variances. The analysis of variance assumes that variances are equal across groups or
samples. The Bartlett test can be used to verify that assumption. When these tests were run there
were only statistical differences in religious well-being and race (see highlighted table for
significant findings and tables in appendix for non-significant findings).
Tables 7: One-way ANOVA – religious well-being and race
Race

Mean

Std Dev.

Frequency

White

30.56

14.54

90

Other

27.40

9.66

88

Source
Between Groups

SS

Df

MS

F

Prob. > F

1525.34

9.52

0.0001

4576.02

3

Within Groups

27874.68

174

160.2

Total

32450.70

177

183.34

Regression models were conducted, religious well-being as it relates to age, existential wellbeing as it relates to age, spiritual well-being as it relates to age, religious well-being as it relates
to FTND, existential well being as it relates to FTND score, spiritual well-being as it relates to
FTND, religious well-being as it relates to cpd, existential well-being as it relates to cpd, spiritual
well-being as it relates to cpd. The regression model were conducted to test the linear
relationship between the dependent and independent variables. The ANOVA examined the
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covariates were categorical (race, etc.) and regression was used for when covariates were
continuous (e.g., age).The only area that was found to be significant was religious well-being as
it relates to age (see highlighted table below for significant findings and the tables in the
appendix for non-significant findings).

Tables 8: Regression model religion to age
Religious

Coef.

[95% Conf. Interval]

Well-being
-.21

Age
Cons

35.39

-.38 -.05
27.55 43.22

Pearson’s Chi Square Test was used for 8 week abstinence as it relates to sex, 8 week
abstinence as it relates to race, 8 week abstinence as it relates to education, 8 week abstinence as
it relates to marital status, 8 week abstinence as it relates to age. A chi square test is used to
analyze the relationship between two categorical variables. There were no significant findings
see tables in appendix)

Research Hypotheses
There were two main research hypotheses that guided this study which are discussed below. An
additional hypothesis was tested in a post hoc analyses.
Research Hypothesis 1
1. Cigarette smokers who participate in a smoking cessation program with higher levels
of spiritual well-being are more likely to quit smoking.
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This hypothesis was tested by using logistic regression models. The models were run to test 8
week abstinence as the outcome and religious well-being, age and race as predictors. Logistic
regression is used for predicting the outcome of a categorical variable based on one or more
predictor variables. Simple logistic regression assumes that the outcome variable is binary (i.e.,
coded as 0 and 1). None of the tests results were found to be significant (see tables in appendix).
Research Hypothesis 2
2. Cigarette smokers with higher levels of spiritual well-being will be less likely to drop
out of the smoking cessation program.
This hypothesis was tested by using the two-sample t-test. The tests were run to determine if
there was a relationship between existential well-being and eligible (actively in study) vs.
withdrew (dropped out of study), religious well-being and eligible vs. withdrew and spiritual
well-being and eligible vs. withdrew. An independent sample t-test is used to compare the
means of a normally distributed interval dependent variable for two independent groups. None
of the test results were found to be significant (see tables in appendix).
Post Hoc Analyses
The explanatory research question that was explored was, does spiritual well-being impact
adherence to treatment (see table 9)? Random effects logistic regression models were used to
examine post hoc questions. The post hoc analyses tested the relationship between weekly patch
usage and religious well-being, existential well-being, spiritual well-being, sex, race and
education. The sample size was 168 instead of 178 because 10 of the participants were missing
patch data. There was a significant relationship between patch usage and religious well-being.
Patch use is defined as daily use used to calculate weekly use. Daily use was coded 0, 1, 2
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depending on how long, which was a binary coding. Then, weekly use (binary) was either 5 or 6
days of weekly use.
Tables 9: Religious Well-being, Sex, Race, Education & Weekly Patch Usage
Variables

OR

[95% Conf. Interval]

Religious Well-being

1.08

1.01

Sex

1.15

2.45

.53

11.36

Race 3

27.93

.13

6219.59

Race 5

12.26

.06

2713.14

Race 7

2.95

.001

6547.57

Edu 3

.02

.001

.79

Edu 4

.17

.01

4.12

Edu 5

.28

.01

8.07

Week 2

.49

.18

1.29

Week 3

.36

.14

.93

Week 4

.49

.18

1.29

Week 5

.54

.20

1.44

Week 6

.36

.14

.93

Week 7

.19

.07

.48

Week 8

.10

.04

.27

_cons

1.29

.001 1045.06

Chapter 5: Discussion, Implications and Conclusions
Findings
There were no significant findings for the main hypotheses concerning the relationship
between the spiritual well-being scale and quitting smoking and spiritual well-being scale and
dropping out of the smoking cessation program. The hypotheses suggested that there would be a
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relationship between spiritual well-being and quit rates and drop-out rates. Although, these main
relationships were not found, there were other significant relationships that may suggest that
these areas should be explored in more depth. Relationships were found between religious wellbeing and patch usage. The findings also suggest there is a relationship between religious wellbeing and race. Lastly, there’s a relationship between religious well-being and age; the older the
participant the higher the religious well-being.
The research study was intended to be a catalyst to determine whether spirituality should play
a part in smoking cessation programs. Concerning the relationship between the spiritual wellbeing scale and quitting smoking and the spiritual well-being scale and dropping out of the
smoking cessation program, there were no significant findings. Although, these main
relationships were not found there were other significant relationships that may suggest these
areas should be explored in more depth. Relationships maybe found at later points, possibly at
the 52 week point.
It should also be taken into account that the overall mean spirituality scores for this study
were low in comparison to previous studies completed with members from religious groups.
For example, the mean spirituality score for a group of 285 Conservative Baptist was 105, while
the mean spirituality score for this current study was 47.37. This could be the reason why
spirituality didn’t have an effect; possibly religious people seek their own networks for quitting
smoking and those who come to the program from this current study are less spiritual (Paloutzian
& Ellison, 1991).
Findings & Literature Review, Discussion and Future Research
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Heinz, et al. (2010), found that spirituality and religious practices suffered during active
addiction but went “hand-in-hand” with recovery. Based on this literature and others like it, this
research hoped to find a significant relationship between quitting and spiritual well-being scores
but no relationship was found.
Some populations may benefit more from a spiritual or religious element to smoking
cessation than others. In Kaholokula’s (2008) study former and current Native American
smokers were studied for the purpose of developing a culturally informed smoking cessation
program. The study consisted of ten focus groups with a total of 52 Native Hawaiian men and
women from a rural community in Hawaii. The transcriptions resulted in 11 strategies, 23
supports and 13 barriers to smoking cessation. Native Hawaiians reported having used more
behavioral and religious/spiritual strategies to quit smoking compared with other smokers.
Religion and spirituality is important in the Native Hawaiian culture and for this reason it was a
vital part in their smoking cessation success (Kaholokula, 2008). This literature suggests that
strength of spiritual well-being is highly related to the group being studied. Future research could
look in to study particular populations. The sample were also highly motivated to quit since they
were treatment seekers. This may have reduced variance.
Religious well-being and age and race seemed to have a relationship and because of this may
need to be explored in a smoking cessation program. In particular, this relationship may be
important in counseling sessions and counseling protocols. The relationship between religious
well-being and patch usage also may suggest how the discussion of religion may help with
medication compliance.

Running Head: Smoking Cessation Treatment

67

The sample size of this study was a slight limitation, however, the larger study is still ongoing
and after more data are collected the data set can be revisited to see if there are any significant
changes with a larger sample size. The scale was also only administered once which could have
been a limitation.
Gonzales and colleagues (2007) noted that patient spiritual resources are increasingly
included in the treatment of medical conditions such as cancers and alcohol and drug
dependence, but use of spiritual resources is usually excluded from tobacco dependence
treatment. Future research could test whether quit rates improve when including a spiritual or
religious component to treatment as compared to treatment as usual.
Conclusion
Gonzales and colleagues’ study concluded that smokers, especially heavy smokers, may be
receptive to using spiritual resources in a quit attempt and that spirituality in tobacco dependence
treatment warrants additional investigation and program development. This current research data
could be reviewed again to look at the relationship between spirituality and quitting based on
amount of cigarettes smoked per day. However, as mentioned, more studies are needed in the
area of spirituality and religion. For this reason future research should continue with so many
unchartered areas of study.
Organized social work in the 20th century tried to distance itself from its origins which were
in the form of religious charity in favor of becoming a scientific and professional enterprise
(Moody, 2005). It is only recently that social work has come to a more favorable view of
religion (Cnaan et al., 1999). This change in viewpoint could be due to recent increase in
research on religion and spirituality. However, this field has more room to grow. The only way
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to better understand these relationships is to continue to study the possible relationships and
strengths of spirituality and religiosity in addiction
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SWB Scale
For each of the following statements circle the choice that best indicates the extent of your agreement or disagreement as it
describes your personal experience:
SA = Strongly Agree
MA = Moderately Agree
A = Agree

D = Disagree
MD = Moderately Disagree
SD = Strongly Disagree

1. I don't find much satisfaction in private prayer with God.

SA MA A D MD SD

2. I don't know who I am, where I came from, or where I'm going.

SA MA A D MD SD

3. I believe that God loves me and cares about me.

SA MA A D MD SD

4. I feel that life is a positive experience.

SA MA A D MD SD

5. I believe that God is impersonal and not interested in my daily situations.

SA MA A D MD SD

6. I feel unsettled about my future.

SA MA A D MD SD

7. I have a personally meaningful relationship with God.

SA MA A D MD SD

8. I feel very fulfilled and satisfied with life.

SA MA A D MD SD

9. I don't get much personal strength and support from my God.

SA MA A D MD SD

10. I feel a sense of well-being about the direction my life is headed in.

SA MA A D MD SD

11. I believe that God is concerned about my problems.

SA MA A D MD SD
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12. I don't enjoy much about life.

SA MA A D MD SD

13. I don't have a personally satisfying relationship with God.

SA MA A D MD SD

14. I feel good about my future.

SA MA A D MD SD

15. My relationship with God helps me not to feel lonely.

SA MA A D MD SD

16. I feel that life is full of conflict and unhappiness.

SA MA A D MD SD

17. I feel most fulfilled when I'm in close communion with God.

SA MA A D MD SD

18. Life doesn't have much meaning.

SA MA A D MD SD

19. My relation with God contributes to my sense of well-being.

SA MA A D MD SD

20. I believe there is some real purpose for my life.
SA MA A D MD SD
_________________________________________________________________________________
SWB Scale © 1982 by Craig W. Ellison and Raymond F. Paloutzian. All rights reserved. Not to be duplicated unless
express written permission is granted by the authors or by Life Advance. See www.lifeadvance.com.

Scoring
Items are scored from 1 to 6, with the higher number representing more well-being.
Negatively worded items (#1, 2, 5, 6, 9, 12, 13, 16, 18) are reversed scored. Odd number items
assess religious well-being: even numbered items assess existential well-being (Paloutizian &
Ellison, 1982). These scores are summed in order to yield three scale scores; one score for RWB,
one score for EWB, and one score for total SWB. RWB and EWB scores can range from 10 to
60. SWB total scores can range from 20 to 120.
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British Journal of Addiction (1991) 86, 1119-1127
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance
Questionnaire
TODD F. HEATHERTON, LYNN T. KOZLOWSKI, RICHARD C. FRECKER & KARL-OLOV
FAGERSTROM^
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Maintenance Therapy: PHONE SCREEN (10.22.10)
OVERALL STUDY STATUS:

PHONE SCREEN DF:

Eligible

Eligible

Ineligible

Ineligible

Refused

Today’s Date: ___________

RA Initials:
___________
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Referral Source: (i.e. Radio,
Newspaper)

NAME:
AGE: ____(If <18 , ineligible)
DOB:___________
ADDRESS:

Date of Source:

CITY:
HOME #: (

STATE:
)

Best time to call:

Description: (i.e. Metro,
WXPN, UPenn)

ZIP:

WORK#: ()
SEX:

M

F

HT:________

WT:_______

May we contact you about other studies at Penn for which you may be eligible?
Do you consider yourself to be Hispanic or Latino

YES

NO

YES

NO

What race do you consider yourself (list options)? White
Black or African Amer.
Amer. Indian or Alaska Native
Asian
Native Hawaiian or other Pacific Islander More than one race : Please list____________________
Unknown
1. Do you smoke menthol or regular cigarettes?

REG

MEN

2. Are you able to communicate in English? (If NO, ineligible)

YES

NO

3. During the past 7 days, how many cigarettes did you smoke on a typical day? (If <10, ineligible)

____

cigs

4. Do you plan to live in the area for at least the next 12 months? (If NO, ineligible)

YES

NO

5. Are you pregnant, breast-feeding, or planning on becoming pregnant in the next 12 months? (If YES,
ineligible)

YES

NO

YES

NO

6. Are you menopausal or unable to have children (i.e. tubal ligation, hysterectomy, etc.) (If YES, proceed to
7;
if NO, proceed; if male, n/a.)
a. Have you used birth-control methods to avoid pregnancy for at least the past month ( i.e. condoms, the
Pill, etc.)? (If YES, proceed; if NO, ineligible)?
b. What type of birth control do/will you use? Specify type: ______________________

YES

NO

7. On a typical week (7 days), about how many glasses of beer, wine, & hard liquor do you drink?
Beer (12 oz.)

____ Wine (6-8 oz.)______ Liquor (1.5 oz.)______

8. Have you ever had a diagnosis of psychosis or schizophrenia (If YES, ineligible)?
YES

NO

YES

NO

YES

NO

9. Have you ever had a diagnosis of bipolar disorder (If YES, ineligible)?
10. Do you currently have heart disease (i.e., current diagnosis or coronary artery disease, an abnormal heart rhythm or
an arrhythmia, heart failure, heart valve disease, congenital heart disease, heart muscle disease or cardio-myopathy,
pericardial disease, aorta disease, or vascular disease)? (If YES, eligible only with physician approval. This can be
Frank or PCP.)
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11. Have you had a heart attack in the last 6 months (If YES, ineligible)?
YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

16. Are you allergic to latex or adhesive tape (If YES, ineligible)?

YES

NO

17. Are you currently taking or recently discontinued (within past 14 days) any of the following (if YES, ineligible)

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

YES

NO

12. Do you have asthma (If YES, eligible only with physician approval)?
13. Do you have diabetes (If YES, eligible only with physician approval)?
14. Do you have an ulcer (If YES, eligible only with physician approval)?
15. Do you have high blood pressure (>160 over 100)? If YES, proceed to question a; If NO, proceed to 16.
a. Are you on medication to control your high blood pressure? (If YES, eligible with physician approval; if NO,
ineligible)

a. AntipsychotIcs (e.g, Haldol/haloperidol, Loxitane, Thorazine/chlorpromazine)?
b. Atypical antipsychotics (e.g., Abilify, Clozaril/clozapine, Risperdal, Seroquel, Zyprexa, Geodon)?
c. Mood stabilizers (e.g., Lithium, Lamictal/lamotrigine, Neurontin/gabapentin, Topamax/topiramate)?
d. Anti-depressants (e.g., tricyclics: Norpramin/desipramine, Elavil/amitriptyline; SSRI's:Lexapro, Prozac, Zoloft;
MAOI's: Nardil, Parnate; Effexor/Effexor XR, Remeron/mirtazepine, Serzone/nefazodone)? (If YES, proceed
to question d2. If NO, proceed to 20)
d2. For what reason and/or diagnosis (If psychosis, schizophrenia or bipolar disorder, INELIGIBLE.
If depression or anxiety, etc. ELIGIBLE)? ___________________________________
18. What medications do you currently take (list all and check for eligibility):
_____________________________________________________________
19. IF ELIGIBLE for study: After hearing the program description, are you interested in coming in for the initial
pre-quit study appointment?

If NO, why?
Time

Not interested

Privacy
issues

Distance

Patch Concerns Doesn’t want to be
randomized Other __________

If YES, eligibility appt. date and time: Date: ______/______/______
Time: ______:______

AM PM

If YES, counseling appt. date and
time: Date: ______/______/______
Time: ______:______ AM PM

UNIVERSITY OF PENNSYLVANIA
RESEARCH SUBJECT
INFORMED CONSENT AND HIPAA FORM
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Protocol Title:
Maintenance Therapy for Nicotine Dependence
Principal
Investigator:

Emergency
Contact:

Robert Schnoll, Ph.D.
Department of Psychiatry, University of Pennsylvania, 3535 Market
Street, 4th Floor, Philadelphia, PA, 19104; (215) 746-7143
Dr. Frank Leone
Department of Pulmonology, University of Pennsylvania
(215) 662-8585; after hours: (610) 506-0163

Why am I being asked to volunteer?

You are being invited to participate in a research study. Your participation is voluntary which
means you can choose whether or not you want to participate. If you choose not to participate,
there will be no loss of benefits to which you are otherwise entitled. Before you can make your
decision, you will need to know what the study is about, the possible risks and benefits of being
in this study, and what you will have to do in this study. The research team is going to talk to
you about the research study, and they will give you this consent form to read. You may also
decide to discuss it with your family, friends, or family doctor. You may find some of the medical
language difficult to understand. Please ask the study doctor and/or the research team about
this form. If you decide to participate, you will be asked to sign this form. You are being asked to
volunteer for this study of treatments for smoking because you are a smoker.

What is the purpose of this research study?

You are being asked to participate in a research study because you are a smoker, meet the
inclusion criteria of the study and have expressed an interest in quitting. The purpose of this
research study is to: (a) compare the effectiveness of 8 weeks (standard treatment) of nicotine
patch treatment versus 24 weeks (extended treatment) of nicotine patch treatment versus 52
weeks (maintenance treatment) of 21mg nicotine patch treatment (14mg or 7mg nicotine
patches will also be available for those participants who may need a lower dose of nicotine);
and (b) examine the role that specific factors may have in whether people quit or not.

How long will I be in the study? How many other people will be in the study?
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You will be asked to be in this study for about 54 weeks. We expect to recruit about 600 people
for this trial.

What am I being asked to do?

At the initial eligibility and pre-quit visits, you will: provide written informed consent and HIPAA
authorization, have a brief medical examination to determine your eligibility for the study; and
complete questionnaires about your smoking habits, behaviors, and mood (2 hours) and have
your first, small-group smoking cessation counseling session (60 minutes; total visit time is 3hours). We may ask you if some of these activities can be recorded or videotaped for quality
assurance purposes. This will only occur with your verbal approval.

During your physical, you will complete an electrocardiogram (ECG) to check your heart
function. An ECG is used to track the electrical activity of your heart over time. To test your
heart function, a research study personnel will place several electrodes (small plastic patches)
to your upper chest. You should not feel any pain. The information gathered from the ECG will
allow us to check that your heart is healthy. You will also be asked to provide two saliva
samples (5 ml saliva each, or about one tablespoon each) to check the nicotine levels in your
blood and to allow us to explore differences in genes between people that may relate to
response to treatment. Because we do not yet understand the role of nicotine metabolism and
genetic differences fully in smoking cessation, you will not receive the results or feedback from
this analysis. If after the medical examination you are eligible, you will begin the 52-week (12month) smoking cessation program.

The cessation program that is part of this study includes nicotine patch treatment and behavioral
counseling. You will be randomly assigned to receive either the standard treatment (8 weeks of
active patch treatment), the extended treatment (24 weeks of the active patch treatment), or the
maintenance treatment (52 weeks of active patch treatment). You will have an equal chance of
being allocated to the groups (this is similar to making a choice by the toss of a coin). It is very
important to use only the nicotine patches given to you as part of this program and to tell the
research staff if you use any medications (including other smoking cessation treatments) while
you are taking part in this program.

The smoking cessation counseling includes one 60 minute in-person small group counseling
session (at tonight’s visit), one 30-minute individual session over the phone that will occur in 2
weeks on your target quit date (study week 0) and then ten, 15 minute individual phone
sessions over the course of the year (Weeks 4, 8, 12, 16, 20, 24, 30, 36, 42, 48). In these
sessions you will learn skills to help you quit smoking and remain smoke free. Each session will
begin with a review of any treatment side effects, an assessment of your smoking practices and
completion of questionnaires that should take about 20 minutes. In total then, you can expect
the monthly study sessions to take about 40 minutes. A study coordinator may listen in to these
study sessions or these sessions may be recorded to ensure the treatment is consistent for all
participants. However, this will only happen with your verbal consent at the start of the call.
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At week 8, week 24, week 36, and week 52 you will be asked to revisit the Center to have your
vitals checked as well as to complete another ECG. If you are a woman of child-bearing
potential, you will also repeat a urine pregnancy test. You will also complete a carbon monoxide
(CO) breath test if you have quit smoking. The purpose of this CO breath test is to verify that
you are smoke-free.

As part of your participation in this study, studies will be conducted with the saliva samples you
provide. These studies will examine biological factors (such as family genetic make-up) related
to smoking and other behaviors. This research will be conducted on an experimental basis
only, and you will not be provided with any additional information about these test results.
Because we want to protect your confidentiality, we will identify your saliva samples with an
identification number only (not your name). Only authorized study personnel will be able to link
your identification number with your name. Your samples will be stored in our private gene
bank, which can be accessed only by authorized study personnel. We will keep your samples
for a maximum of 10 years after study completion. At that time, your saliva samples will be
destroyed and we will break the link identifying your name with your saliva samples. However,
you can request that your samples be destroyed at any time after the study is completed.
Please circle “yes” or “no” and sign your initials on the line to give us permission to store your
saliva samples in a private gene bank for a maximum of 10 years.
YES, I give permission to have my saliva stored for up to 10 years
NO, I do not give permission to have my saliva stored for up to 10 years.
______ (Initials)

What are the possible risks or discomforts?

The potential risks to participants, and their likelihood and seriousness, are described below.
You can choose, as an alternative, to not enroll in this study. Overall, there is minimal risk for
serious adverse reactions as a consequence of enrolling in this study.

Assessment: You may experience emotional distress during assessments from discussing
feelings and attitudes about smoking or from learning about the risks from smoking. These
events happen very rarely and in almost all cases are short-lived and of low intensity, lasting
for 1-2 weeks. Study personnel will be alerted to expect this from a small number of subjects
and will be trained to make referrals for mental health services as needed. Personnel will be
trained to query for adverse emotional reactions during assessments and will be trained to
deal with such reactions and to provide additional referrals if needed. In addition, if
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assessments indicate psychiatric concerns, referrals to appropriate psychological services will
be provided.

Nicotine Replacement Therapy (NRT): Nausea, vomiting, weakness, diarrhea, dizziness,
and rapid heart beat occur rarely and are most often caused by continuing to smoke while
using the patch. Another possible side effect of regular smoking while wearing the patch is
elevated blood pressure. If these reactions occur, you can call the Emergency Contact listed
on page 1 of this form and/or your doctor. If these reactions occur as a consequence of
concurrent patch and tobacco use, you may be asked to stop using the patch, reestablish the
quit day, and restart cessation attempts. We will not require that you remove the patch if you
return to smoking, unless you are experiencing side effects that concern you. Instead, we will
advise that you continue to wear the patch and work with your counselor to try and quit
smoking again. The risk of adverse response to the patch will be minimized by admitting you
to the study only if you do not have preexisting conditions that increase the risk for these
reactions (i.e., serious heart disease). Some individuals who use the patch experience minor
skin irritation, such as redness, rash, or minor swelling, and insomnia and dream
abnormalities. Insomnia and dream abnormalities can be resolved by removing the patch
during the night while sleeping. All of these reactions cease once the patch is removed. You
should not stop using the patch without discussing your symptoms with the study physician.

Reproductive Risks: Because NRT safety for an unborn baby is unknown, participants will
be told that they should not become pregnant while on this study. If you are currently
pregnant, it is important that you inform the investigator because you will not be able
participate in the study. If you are able to become pregnant, you will be given a pregnancy
test before entry into the study as well as repeat pregnancy tests at weeks 8, 24, 38 and 52.
You are asked to use a medically accepted method of birth control while you participate in the
study. You should not become pregnant while you are using the nicotine patches. If you do
become pregnant, you must tell the investigator and consult an obstetrician or maternal-fetal
specialist immediately. If you become pregnant during the study, you will discontinue the study
medication and will be asked to remain on study completing only the counseling and study
questionnaires. We will follow your pregnancy to collect information regarding adverse events
and complications, as well as, information about the outcome of your pregnancy. If your
pregnancy results in a live birth, we will collect general health outcome information pertaining
to your child for a period of up to two weeks.

Withdrawal Syndrome: Many people who quit smoking exhibit a pattern of symptoms related
to withdrawal from tobacco use. These symptoms include: sadness and anxiety, irritability,
anger, difficulty concentrating, appetite change and weight gain, insomnia, and decreased
heart rate. Eliminating the risk for these would not be possible, although in most cases these
events are short-lived and have low intensity, lasting for 2-4 weeks. The study personnel will
be trained to recognize these symptoms and educate you about them (e.g., their duration,
methods for reducing them). Use of the patch will minimize the severity of withdrawal.

Threats to Privacy/Confidentiality: Since self-report and biological data will be collected and
stored as part of this study, it is possible that your privacy or confidentiality can be threatened.
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Study sites have sophisticated computer systems to prevent the unauthorized access to study
data and sites have long-established protocols to guard against improper use of hard copies
of data (e.g., locked files, numeric coding procedures). The present research team has not
experienced the unauthorized use of study data. A web-based data collection procedure will
minimize the possibility of loss of privacy or confidentiality.

What if new information becomes available about the study?

During the course of this study, we may find more information that could be important to you.
This includes information that, once learned, might cause you to change your mind about being
in the study. We will notify you as soon as possible if such information becomes available.
What are the possible benefits of the study?
The direct benefit you may receive from participating in this study is that you may quit smoking
completely or decrease the amount of your smoking.

What other choices do I have if I do not participate?

If you do not participate in this smoking cessation study, you can investigate additional quitsmoking options that may be available through other organizations like the National Cancer
Institute. You may quit without any assistance or you may continue to smoke.

Will I be paid for being in this study?

As a token of our appreciation for participating in the study, you may be paid up to $180 for
participating in counseling sessions and completion of measures. You will also be asked to
attend the site to provide additional measures (as described under the section, “what am I being
asked to do” above); you will receive an additional $15/visit for completing these in-person
assessments as well as a $15 stipend for travel costs. Payments for completing the phone
based sessions ($15 per session) will be cumulated, and you will be paid in cash following your
completion of the in-person visits after Weeks 8, 24, 36, and 52. For example, if you complete
the study sessions on weeks 0, 4, and 8, at the end of the Week 8 in-person visit, you will
receive $45 plus the $30 for completing the in-person visit. The most you will receive at one
time is $90 cash.
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SCHEDULE OF INCENTIVE PAYMENT
AFTER COMPLETION OF THIS SESSION
Week 0
Week 4
Week 8
Week 8 in-person visit
Week 12
Week 16
Week 20
Week 24
Week 24 in-person visit

YOU WILL BE PAID
$15
$15
$15
$45 + $30 = $75
$15
$15
$15
$15
$60 + $30 = $90

Week 30
Week 36
Week 36 in-person visit

$15
$15
$30 + $30 = $60

Week 42
Week 48
Week 52
Week 52 in-person visit

$15
$15
$15
$45 + $30 = $75
Up to $300

Will I have to pay for anything?

There will be no charge to you for participating in this research study. You will receive the quit
smoking counseling and nicotine patch at no cost to you. You also may be reimbursed for
parking and public transportation expenses related to your participation in the study.

What happens if I am injured or hurt during the study?

If you have a medical emergency during the study you should go to the nearest emergency
room. You may contact the Principal Investigator or Emergency contact listed on page one of
this form. You may also contact your own doctor, or seek treatment outside of the University of
Pennsylvania. Be sure to tell the doctor or his/her staff that you are in a research study being
conducted at the University of Pennsylvania. Ask them to call the telephone numbers on the
first page of this consent form for further instructions or information about your care. In the event
that you are hurt or injured as a result of participation in this research study, please contact the
investigator listed on page one of this form.
We will offer you the care needed to treat injuries directly resulting from taking part in this
research. We may bill your insurance company or other third parties, if appropriate, for the
costs of the care you get for the injury, but you may also be responsible for some of them.
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There are no plans for the University of Pennsylvania to pay you or give you other
compensation for the injury. You do not give up your legal rights by signing this form.

If you think you have been injured as a result of taking part in this research study, tell the person
in charge of the research study as soon as possible. The researchers’ name and phone
number are listed in the consent form.

When is the Study over? Can I leave the Study before it ends?

This study is expected to end after all participants have completed all visits, and all information
has been collected. This is expected to take more than 5 years. This study may also be stopped
at any time by your physician, the study Sponsor, or the Food and Drug Administration (FDA)
without your consent because:
• The Primary Investigator feels it is necessary for your health or safety. Such an action
would not require your consent, but you will be informed if such a decision is made and
the reason for this decision.
• You have not followed study instructions.
• The Sponsor, the study Principal Investigator, or the Food and Drug Administration
(FDA) has decided to stop the study.
If you decide to participate, you are free to leave the study at anytime. Withdrawal will not
interfere with your future care.
Who can see or use my information? How will my personal information be protected?
We will do our best to make sure that the personal information in your medical record and the
study record will be kept private. However, we cannot guarantee total privacy. Your personal
information may be given out if required by law. If information from this study is published or
presented at scientific meetings, your name and other personal information will not be used. If
this study is being overseen by the Food and Drug Administration (FDA), they may review your
research records. Please refer to the HIPAA portion of this document that explains more
specifically how your personal information will be protected.
Electronic Medical Records and Research Results: What is an Electronic Medical Record?

An Electronic Medical Record (EMR) is an electronic version of the record of your care within a
health system.
An EMR is simply a computerized version of a paper medical record.
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If you are receiving care or have received care within the University of Pennsylvania Health System
(UPHS)
(outpatient or inpatient) and are participating in a University of Pennsylvania research study, results
of
research related procedures (i.e. laboratory tests, imaging studies and clinical procedures) may
be placed in
your existing EMR maintained by UPHS.

Once placed in your EMR, these results are accessible to appropriate UPHS workforce members
that are not
part of the research team. Information within your EMR may also be shared with others who are
determined
by UPHS to be appropriate to have access to your EMR (e.g. health insurance company, disability
provider,
etc).

Who can I call with questions, complaints or if I’m concerned about my rights as a
research subject?

If you have questions, concerns or complaints regarding your participation in this research study
or if you have any questions about your rights as a research subject, you should speak with the
Principal Investigator listed on page one of this form. If a member of the research team cannot
be reached or you want to talk to someone other than those working on the study, you may
contact the Office of Regulatory Affairs with any question, concerns or complaints at the
University of Pennsylvania by calling (215) 898-2614.
Financial Disclosure

Dr. Schnoll, the principal investigator leading this medical research study, serves as a
consultant to Glaxo Smith Kline, one of several companies that manufactures the nicotine patch.
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However, Glaxo Smith Kline is not involved with this study. If you would like more information,
please ask the researchers or the study coordinator.

When you sign this form, you are agreeing to take part in this research study. This means that
you have read the consent form, your questions have been answered, and you have decided
to volunteer. Your signature also means that you are permitting the University of Pennsylvania
to use your personal health information collected about you for research purposes within our
institution. You are also allowing the University of Pennsylvania to disclose that personal health
information to outside organizations or people involved with the operations of this study.
What personal health information is collected and used in this study and might also be
shared (disclosed)?
The following personal health information will be collected, used for research, and may be
disclosed or released during your involvement with this research study:
- Name
- Address
- Telephone number
- Your medical history
- Allergies
- Current and past medications
- Information from a physical examination that generally also includes blood pressure
reading, heart rate, breathing rate and temperature
- Smoking behavior and history and alcohol use
- Pregnancy status
- Attitudes and beliefs about smoking
- Psychological well-being, withdrawal effects
Why is your personal health information being used?
Your personal contact information is important for the University of Pennsylvania Health System
and School of Medicine research team to contact you during the study. Your health information
and results of tests and procedures are being collected as part of this research study and for the
advancement of medicine and clinical care. The Principal Investigator may also use the results
of these tests and procedures to treat you.
Which of our personnel may use or disclose your personal health information?
The following individuals and organizations may use or disclose your personal health
information for this research project:
- The Principal Investigator and the Investigator’s study team (other University staff
associated with the study)
- The University of Pennsylvania Institutional Review Boards (the committees charged
with overseeing research on human subjects) and University of Pennsylvania Office of
Regulatory Affairs
- The University of Pennsylvania Office of Human Research (the office which monitors
research studies)
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Authorized members of the University of Pennsylvania and the University of
Pennsylvania Health System and School of Medicine workforce who may need to
access your information in the performance of their duties (for example: to provide
treatment, to ensure integrity of the research, accounting or billing matters, etc.).

Who, outside of the University of Pennsylvania Health System and the School of
Medicine, might receive your personal health information?
As part of the study, the Principal Investigator, study team, and others listed above, may
disclose your personal health information, including the results of the research study tests and
procedures to the following:
-

-

Government agency and/or their representative: The National Institutes of Health (study
sponsor) will receive regular reports about this study which may include your personal
health information since they need to confirm the accuracy of the results and the proper
use of funds that support this study.
Food and Drug Administration (FDA)

The Principal Investigator or study staff will inform you if there are any changes to the list above
during your active participation in the trial. Once information is disclosed to others outside the
University of Pennsylvania Health System or School of Medicine the information may no longer
be covered by the federal privacy protection regulations.
In all disclosures outside of the University of Pennsylvania Health System and School of
Medicine, you will not be identified by name, social security number, address, telephone
number, or any other direct personal identifier unless disclosure of the direct identifier is
required by law.
In records and information disclosed outside of the University of Pennsylvania Health System
and School of Medicine, you will be assigned a unique code number. The Principal Investigator
will ensure that the key to the code will be kept in a locked file. The key to the code will be
destroyed at the end of the research study.
How long will the University of Pennsylvania Health System, the School of Medicine and
the study Sponsor be able to use or disclose your personal health information?
Your authorization for use of your personal health information for this specific study does not
expire. This information may be maintained in a research repository (database). However, the
University of Pennsylvania Health System and School of Medicine may not re-use or re-disclose
your personal health information collected in this study for another purpose other than the
research described in this document unless you have given written permission for the Principal
Investigator to do so. However, the University of Pennsylvania Institutional Review Board may
grant permission to the Principal Investigator or others to use your information for another
purpose after ensuring that appropriate privacy safeguards are in place. The Institutional
Review Board is a committee whose job it is to protect the safety and privacy of research
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subjects. Results of all tests and procedures done solely for this research study and not as part
of your regular care will not be included in your medical record.
Will you be able to access your records?
You will be able to request access to your medical record when the study is completed. During
your participation in this study, you will not be able to access your medical records. This will be
done to prevent the knowledge of study results from affecting the reliability of the study. Your
information will be available should an emergency arise that would require your treating
physician to know this information to best treat you. You will have access to your medical
record and any study information that is part of that record when the study is over or earlier, if
possible. The investigator is not required to release to you research information that is not part
of your medical record.
Can you change your mind?
You may withdraw your permission for the use and disclosure of any of your personal
information for research, but you must do so in writing to the Principal Investigator at the
address on the first page. Even if you withdraw your permission, the Principal Investigator for
the research study may still use your personal information that was collected prior to your
written request if that information is necessary to the study. If you withdraw your permission to
use your personal health information that means you will also be withdrawn from the research
study.

You will be given a copy of this Research Subject Authorization Form describing your
confidentiality and privacy rights for this study. You will also be given the University of
Pennsylvania Health System and School of Medicine’s Notice of Privacy Practices that contains
more information about the privacy of your health information.

By signing this document you are permitting the University of Pennsylvania Health System and
School of Medicine to use and disclose personal health information collected about you for
research purposes as described above.
A copy of this consent and HIPAA authorization form will be given to you.

________________________
Name of Subject (Please Print)

________________________

____________________________________
Signature of Subject

Date

_____________________________________
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